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The increasing incidence of human candidiasis and the tendency of Candida species to become resistant
to existing chemotherapies are well-recognized health problems. The present study demonstrates the
successful synthesis of novel triazole–amino acid hybrids with potent in vitro and in vivo inhibitory activity
against Candida species. Particularly, compounds 68 and 70 showed potent in vitro activity against fluco-
nazole (FLC) resistant as well as sensitive clinical isolates of Candida albicans. Time kill curve analysis of
lead inhibitors 68 and 70 showed their fungistatic nature. Secretion of hydrolytic enzymes, mainly pro-
teinases and phospholipases, decreased considerably in the presence of 68 and 70 indicating their inter-
ference in fungal virulence. TEM analysis of Candida cells exposed to compounds 68 and 70 clearly
showed morphological changes and intracellular damage as their possible mode of action. A preliminary
mechanistic study carried out on the two most effective inhibitors (68 and 70) revealed the inhibition of
ergosterol biosynthesis thereby causing the cells to lose their integrity and viability. The selected com-
pounds did not show significant cytotoxicity up to a concentration of 200 µg mL−1 in the HEK293 cell
line. An in silico analysis of 68 and 70 binding to a modeled C. albicans CYP51 showed critical H-bonding
as well as hydrophobic interactions with the important active site residues indicating the basis of their
anti-Candida role. Studies on the larvae of Galleria mellonella showed that the selected inhibitors (68 and
70) were non-toxic, did not provoke an immune response and significantly reduced Candida proliferation
in vivo.
Introduction
Over the past three decades, the frequency of fungal infections
in humans has increased dramatically worldwide despite the
extensive efforts towards the discovery of novel antifungal
agents and the availability of various drugs.1–3 Of particular
concern is the severity associated with the ever-increasing inci-
dences of hospital-acquired systemic mycoses, caused by
various species of Candida, responsible for the crude mortality
rate of up to 50% in the United States alone.4 Adding to this
disease burden, superficial infections of skin and nails in
humans are affecting ∼25% of the general population world-
wide.5 It has been reported that the use of broad-spectrum
antibiotics, suppression of immune response during organ
and bone marrow transplantation, cancer treatment and AIDS
are increasing the chances of Candida infections thus further
aggravating the condition.6 Among many Candida species,
C. albicans is a prominent Candida species which is respon-
sible for a major cause of candidiasis and isolated from
approximately 80% of cases of candidemia.7 However, the
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number of infections caused by other non-Candida albicans
Candida species (NCAC) which include C. glabrata, C. tropicalis
and C. parapsilosis has also increased.8
During both superficial and systemic infection, pathogen-
icity of Candida species relies on a number of virulence factors
including the capability to adhere onto the surface that assists
them to colonize the host. Adhesion is mainly influenced by
the profile of cell wall proteins and cell surface physico-
chemical properties.9 In addition to this, they also adhere to
the surface of medical devices and form biofilms which limit
the penetration of substances through the matrix and decrease
the susceptibility of Candida to antifungal therapy.10 Candida
also secrete different hydrolytic enzymes like proteinases,
phospholipases and hemolysins and acquire nutrients and dis-
seminate within the host. They also modulate the host
immune response and cause destruction of host tissues.11
Treatment of Candida infections relies on a limited number
of chemotherapeutic agents including polyenes, azoles, echi-
nocandins, allylamines and flucytosine.12 Among them, azoles
such as fluconazole (FLC), itraconazole, voriconazole, posaco-
nazole, ketoconazole, miconazole and econazole (Fig. 1) are
widely used for the treatment of both superficial and invasive
fungal infections due to their favourable pharmacokinetics
and safety profile.6 Azoles target the biosynthesis of ergosterol,
a major component of the fungal membrane, by inhibiting
the cytochrome P450-dependent enzyme lanosterol
14α-demethylase (CYP51). The depletion of ergosterol and
accumulation of toxic methylsterols in the membrane result in
the alteration of membrane fluidity along with disruption of
activity of membrane-bound enzymes leading to the inhibition
of fungal growth and replication.13 Although azoles have an
advantage of oral administration, they lack fungicidal effects
as well as possess limited selectivity for fungal demethylase
enzyme over mammalian cytochrome P450s thus posing
serious side effects.14 Moreover, the increased use of azole
antifungals has contributed to the emerging resistance in
Candida species which is prompting the medicinal chemists
worldwide to develop novel and more effective antifungal
agents with a broad spectrum, better pharmacokinetic profile
and low toxicity.15
Previously, it was reported that triazole–amino acids
clubbed with an indole moiety have potent antifungal effects
as they caused detrimental effects on the sterol biosynthetic
pathway of C. albicans thus inducing cell wall defects leading
to cell death in combination with currently available azole
antifungals.16 On the basis of these findings on triazole–
amino acid scaffolds and in continuation of our efforts for the
development of antimicrobial agents,17–19 we report herein the
synthesis of a series of novel triazole–amino acid hybrids
(65–88) and their screening against three species of Candida
(C. albicans, C. glabrata and C. tropicalis). This leads to the
identification of 1,2,3-triazoles bearing phenylalanine (68) and
tryptophan tails (70) as potent antifungals against FLC sensi-
tive and resistant clinical isolates of C. albicans. Moreover,
compounds with comparatively lower IC50 values were also
subjected to cell proliferation assay on the HEK293 (Human
Embryonic Kidney) cell line and were found to be non-toxic up
to a 200 µg mL−1 concentration. Various assays for growth
(time kill curve) and virulence (proteinase and phospholipase
secretion) performed on Candida cells exposed to lead inhibi-
tors (68 and 70) also showed promising results. A detailed
study of lead compounds (68 and 70) on the larvae of Galleria
mellonella further confirmed their non-toxic behavior and a
significant reduction in Candida proliferation in vivo. Because
of the importance of CYP51 in the antifungal drug studies,
molecular docking was performed for the most active com-
pounds against the predicted three-dimensional model of
CYP51 from C. albicans in order to shed light on the mechan-
ism and plausible binding modes of the compounds to the
target enzyme. Our study revealed that the triazole–amino acid
hybrids (68 and 70) provide a suitable core to be exploited for
lead optimization to develop potent antifungal agents.
Results and discussion
Chemistry
The multistep synthetic approach was adopted for the prepa-
ration of the title compounds (65–88) as given in Scheme 1.
Substituted benzylamines (17–24) were obtained via a two-step
sequence involving oximation of substituted aryl aldehydes
(1–8) followed by Zn/HCl mediated reduction.18 Then, in
another set of reactions azidopropionic acid, 26, was obtained
from 3-bromopropionic acid, 25, by direct azide replacement
using sodium azide in anhyd. DMF at 85 °C. Coupling of
azidopropionic acid, 26, with substituted benzylamines 17–24
in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodi-
imide (EDC·HCl) and 1-hydroxybenzotriazole (HOBt) in aceto-
nitrile yielded the corresponding azide intermediates 27–34 in
moderate yield. In a separate set of reactions, boc-protected
L-amino acids (35–37) were treated with propargyl bromide inFig. 1 Structure of common azole-based antifungal drugs.
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the presence of K2CO3 to provide alkyne intermediates (39–40)
in excellent yield. Finally, the 1,2,3-triazole–amino acid
hybrids (41–64) were synthesized via the Huisgen 1,3-dipolar
cycloaddition reaction between alkynes 39–40 and azides
27–34 in the presence of copper sulphate and sodium ascor-
bate in a tert-butanol : water (1 : 2) mixture. The key intermedi-
ates, 41–64 were finally deprotected utilizing p-toluenesulfonic
acid in dichloromethane to yield title compounds 65–88 in
high yield (Table 1).
In vitro anti-Candida activity
We generated a library of 24 compounds that features the
1,2,3-triazole core and an amino acid (Phe/Pro/Trp) as a tail
and screened all the analogues for in vitro anticandidal
activity. Preliminary studies were done on three different
Candida species: C. albicans, C. glabrata and C. tropicalis to see
the effect of these analogues on the growth of Candida cells
in vitro (Table 2). Fluconazole was used as a positive control.
The unsubstituted and para-halogen substituted benzyl com-
pounds with an L-phenylalanine tail showed modest activity
(70.9–179.4 µg mL−1) against most pathogenic C. albicans
ATCC 90028 strain. Compound 68 with p-fluoro substitution
and a phenylalanine tail emerged as the most potent (IC50 =
70.9 µg mL−1) among all in the series as a selective inhibitor of
C. albicans ATCC 90028 strain. Chloro substitution at the ortho
position to the benzyl group (74) resulted in the decrease of
activity (340.0 µg mL−1) in the same strain. The structure-
activity relationship could not be established clearly in the
case of analogues with an L-proline tail. Moreover, compound
66 bearing an unsubstituted benzyl group and an L-proline tail
exhibited an IC50 value of 203.5 µg mL
−1 in C. glabrata ATCC
90030 strain. It was found that the unsubstituted and para-
substituted triazole analogues with a tryptophan tail showed
the best anticandidal activity against C. albicans ATCC 90028
strain. Compound 70 with p-fluoro substitution emerged as
the most potent anticandidal agent (IC50 = 22.4 µg mL
−1) com-
pared to 67, with no substitution, having IC50 = 98.8 µg mL
−1
against C. albicans ATCC 90028 strain. It also inhibited the
growth of C. glabrata with an IC50 of 163.2 µg mL
−1. The
p-methyl (79, IC50 = 168.7 µg mL
−1) and p-methoxy (82, IC50 =
163.9 µg mL−1) substitution were well tolerated compared to
p-trifluoromethyl (85, IC50 = 282.6 µg mL
−1) and p-trifluoro-
methoxy (88, IC50 = 1142.7 µg mL
−1) substitution where the
activity was completely lost against C. albicans ATCC 90028
strain. Based on the results obtained with standard Candida
strains, seven compounds (67, 68, 70, 71, 73, 79 and 82) were
selected for further investigation against both FLC-sensitive
and resistant clinical C. albicans strains. Compounds with
p-fluoro substitution with phenylalanine (68) and tryptophan
(70) tails emerged as the most potent inhibitors for clinical
strains too. Compound 68 showed a moderate inhibitory effect
on clinically isolated C. albicans with IC50 in the range of
154.9–188.3 µg mL−1. Similarly, compound 70 also showed
inhibition of clinically isolated Candida cells with IC50 in the
range of 149.63–176.1 µg mL−1. Both compounds, 68 and 70
showed potent inhibitory activity against FLC-resistant
C. albicans with IC50 values of 671.08 and 634.98 µg mL
−1,
respectively, which otherwise is tolerant to FLC (IC50 > 1000 µg
mL−1) (Table 3). The results prompted us to further explore the
effect of these two lead inhibitors (68 and 70) on the growth of
Candida sp. The fungistatic or fungicidal nature of lead com-
pounds (68 and 70) was determined by time kill curve studies
Scheme 1 Synthesis of triazole–amino acid hybrids. Reagents and conditions (a) NH2OH·HCl, pyridine/ethanol (1 : 10), reflux; (b) Zn, HCl, ethanol,
rt; (c) NaN3, DMF, reflux; (d) HOBt, EDC·HCl, NMM, CH3CN, rt; (e) propargyl bromide, K2CO3, DMF, rt; (f ) CuSO4·5H2O, sodium ascorbate, tert-
butanol : water (1 : 2), rt; (g) pTSA, DCM, rt.
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on FLC-sensitive as well as resistant strains of C. albicans. Both
compounds showed a fungistatic effect on the growth of
C. albicans with an efficacy much superior to that of the con-
ventional standard drug fluconazole. Furthermore, no signifi-
cant changes in growth were observed at the concentrations
lower than 120 µg mL−1 of compounds 68 and 70 (Fig. 2).
Extracellular hydrolytic enzymes (e.g. phospholipases and
proteinases) are potent virulence factors which play an impor-
tant role in the establishment of Candida infection.20 To inves-
tigate whether the lead compounds (68 and 70) have any effect
on the extracellular secretion of these enzymes, an inhibition
Table 3 In vitro anticandidal activity of selected potential compounds
against clinical isolate of C. albicans
Compound *C. alb. *C. alb. *C. alb. †C. alb.
67 192.86 343.63 322.05 >1000
68 154.92 188.37 183.13 671.08
70 149.63 153.19 176.10 634.98
71 387.90 206.48 368.69 >1000
73 237.52 358.43 344.70 >1000
79 563.93 249.64 258.77 >1000
82 297.62 199.52 341.76 >1000
FLC <7.81 <7.81 <7.81 >1000
Abbreviations: *C. alb. = C. albicans (fluconazole sensitive); †C. alb. =
C. albicans (fluconazole resistant).
Table 1 Structure of triazole–amino acid hybrids
Benzylamine L-Phenylalanine L-Proline L-Tryptophan
Table 2 In vitro anticandidal activity of compounds 65–88 (IC50 in µg
mL−1) against standard strains of Candida
Comp. C. alb. C. gla. C. tro. 1C. alb.
65 179.4 506.5 364.7 377.0
66 473.8 203.5 741.5 541.3
67 98.8 944.1 475.7 303.7
68 70.9 1352.0 503.0 335.6
69 326.3 912.2 678.9 369.3
70 22.4 163.2 349.0 269.5
71 164.1 1065.3 389.4 314.9
72 420.2 267.4 927.1 351.8
73 161.0 975.5 556.4 313.3
74 340.0 383.6 421.4 303.5
75 376.0 247.5 852.0 333.8
76 227.1 684.3 542.3 378.7
77 294.4 851.3 497.7 300.3
78 478.7 326.9 684.3 636.5
79 168.7 1074.0 618.3 379.0
80 300.2 1121.1 447.8 292.7
81 554.0 265.6 571.2 562.3
82 163.9 427.2 423.6 340.9
83 315.3 371.1 407.6 310.0
84 526.0 268.3 468.0 580.3
85 282.6 272.4 662.3 321.3
86 865.4 1103.7 923.8 747.2
87 985.0 1006.4 971.4 966.0
88 1142.7 1081.6 991.0 998.8
FLC 15.6 7.8 8.5 n.d.
Abbreviations: C. alb. = C. albicans ATCC 90028; C. gla. = C. glabrata
ATCC 90030; C. tro. = C. tropicalis ATCC 750; 1C. alb. = C. albicans
ATCC 1026; n.d. = not done; NA = not active; FLC = fluconazole.
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assay was performed using standard as well as resistant
C. albicans strains. The results showed that on treatment with
120 µg mL−1 of compound 68, proteinase secretion was
decreased by 29, 22 and 23.5% in standard, FLC-sensitive and
resistant strains of C. albicans, respectively, while at the same
concentration, compound 70 decreased the proteinase
secretion by 30, 33 and 17% against the respective strains.
Similar results were obtained at a 60 µg mL−1 concentration of
both compounds, 68 and 70, with no significant differences in
the inhibition of proteinase secretion (Fig. 3A). At similar con-
centrations, compound 68 caused 40, 38, and 38% inhibition
in phopholipase secretion whereas compound 70 decreased
the secretions respectively by 36, 27 and 38% in standard,
FLC-sensitive and resistant strains of C. albicans (Fig. 3B). Our
results suggest that both compounds (68 and 70) significantly
reduce the secretion of proteinases and phospholipases in
Candida spp. which are vital to fungal invasion of host tissues
and immunosuppression.
The effect of lead compounds (68 and 70) on the mor-
phology of C. albicans was monitored by transmission electron
microscopy (TEM) which led to the exploration of the possible
antifungal mechanism of action. Candida cells treated with
120 µg mL−1 of 68 and 70 and the untreated control cells were
used for TEM analysis. It was observed, as shown in Fig. 4,
Fig. 2 Time kill curves of (A) fluconazole sensitive C. albicans ATCC
90028; (B) fluconazole resistant C. albicans at various concentrations of
68 and 70. The results indicate the fungi-static nature of these
compounds.
Fig. 3 Effect of compounds 68 and 70 on (A) proteinase secretion and;
(B) phospholipase secretion. These hydrolytic enzymes act as a potent
virulence factor and play an important role in the establishment of
Candida infection. The higher Pz value indicates the lower secretion of
enzyme. At a 125 µg mL−1 concentration, compounds 68 and 70 cause
17 to 38% decrease in secretion of these enzymes.
Fig. 4 Representative transmission electron micrographs of C. albicans
ATCC 90028 cells exposed to 68 and 70 at their respective MICs. The
figure showed significant damage to Candida cells. The shape of the cell
became abnormal and the cell wall lost its integrity, became irregular
and ruptured.
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that the untreated cells are normal in shape with uniform cell
density and an intact cell wall while the treated cells showed
several deformations. On exposure to 68 or 70, significant
damage could be seen in Candida cells wherein the cell shape
became abnormal and the cell wall lost its integrity becoming
irregular and ruptured. The intracellular organelles dis-
appeared indicating the necrotic mode of cell death. Thus, we
can conclude from the results of TEM analysis that the lead
compounds (68 and 70) may be interfering with the bio-
synthesis of the cell membrane.
It is well known that azole drugs like FLC inhibit ergosterol
biosynthesis by destroying both membrane integrity and the
function of some membrane-bound proteins and therefore
affecting fungal cell growth and proliferation.21 The effect of
the lead compounds (68 and 70) was studied on ergosterol bio-
synthesis in C. albicans to further support our suggestion that
these compounds interfere with the biosynthesis of the cell
membrane. The ergosterol content of the exposed cells was
estimated in FLC-sensitive and resistant Candida cells by a
method reported previously by Arthington-Skaggs et al.22 and
FLC was used as a positive control. The results showed a dose
dependent decrease in the ergosterol content when the cells
were grown in varying concentrations of 68 and 70 (Fig. 5). The
mean decrease in the total ergosterol content for standard
strains was found to be 5% at 30 µg mL−1, 27% at 60 µg mL−1
and 73% at 120 µg mL−1 of compound 68. The mean decrease
in the total ergosterol content for FLC-resistant C. albicans was
found to be 2% at 30 µg mL−1, 23% at 60 µg mL−1 and 79% at
120 µg mL−1 of compound 68. Similarly, the mean decrease in
the total ergosterol content for standard C. albicans was found
to be 15% at 30 µg mL−1, 37% at 60 µg mL−1 and 48% at
120 µg mL−1 of 70. However, the decrease in the total ergo-
sterol content for FLC-resistant C. albicans was 7% at 30
µg mL−1, 80% at 60 µg mL−1 and 91% at 120 µg mL−1 of 70. In
the presence of 100 µg mL−1 of FLC, the decrease in the ergo-
sterol content was 25% and 28%, respectively, for standard
and FLC-resistant C. albicans (Fig. 5). Our results suggest that
compounds 68 and 70 inhibit the total ergosterol content
more effectively in comparison to FLC in all the Candida
strains tested here. In conclusion, the lead compounds (68
and 70) caused ergosterol depletion resulting in the disruption
of the cell membrane which is consistent with the results of
TEM analysis.
The cytotoxicity of the compounds with comparatively lower
IC50 values (65, 67–71, 73–74, 79, 82–83, 85) was checked by
the MTT assay using the HEK293 cell line (Fig. 6). It is evident
from the results that all the twelve selected compounds (65,
67–71, 73–74, 79, 82–83, 85) displayed more than 85% cell via-
bility at 50 µg mL−1 concentration. Out of 12, eight com-
pounds (67–71, 73, 79, 82–83) displayed more than 70% cell
viability even at a concentration of 200 µg mL−1 which indi-
cated the non-cytotoxic nature of these compounds. On
increasing the concentration from 400 to 600 µg mL−1 for all
the selected compounds, the cells were found to be more than
50% viable. The hemolytic assay was also performed with lead
inhibitors 68 and 70 to exclude any possible toxicity on human
RBCs. At 125 µg mL−1, compounds 68 and 70 caused 10% and
15% cell lysis, respectively, in comparison to 36% cell lysis
caused by FLC at the same concentration (Fig. 7). More inter-
estingly, compounds 68 and 70 were found negligibly toxic up
to 500 µg mL−1, with only 18% and 22% cell lysis, respectively.
Modeling and in silico docking
The lanosterol 14-α demethylase enzyme (CYP51) is a member
of the cytochrome P450 superfamily which catalyses the
Fig. 5 UV spectrophotometric sterol profiles of (A) fluconazole sensi-
tive standard C. albicans ATCC 90028 and; (B) fluconazole resistant
C. albicans. At 120 µg mL−1, the mean decrease in total ergosterol
content for standard as well as resistant C. albicans were found in the
range of 48–96%. Fig. 6 Cell viability assay on the HEK293 cell line.
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oxidative removal of the 14-α methyl group from lanosterol in
the ergosterol biosynthesis pathway. Inhibition of CYP51 is
shown to directly deplete ergosterol resulting in the inhibition
of fungal growth, making it the primary target for the azole
based antifungal drugs.23 Our results have established that the
synthesis of ergosterol is inhibited, which may cause defor-
mation of the cell membrane and its leakage indicating a clas-
sical azole based effect on the fungal CYP51. CYP51 is a mem-
brane bound protein that is difficult to purify and structural
assessment is only possible by modelling closely related struc-
tures. In this study, we have modeled C. albicans like CYP51
from S. cerevisiae. A structure based sequence alignment
showed that CYP51 from S. cerevisiae has 65% sequence homo-
logy with the CYP51 of C. albicans (Fig. 8). The crystal structure
of S. cerevisiae CYP51 (PDB.4LXJ) was used as a template to
construct a model of C. albicans CYP51. The model was further
refined using energy minimization and molecular dynamics
simulation. We generated 5 model structures for CYP51 from
C. albicans and checked their Ramachandaran plot values.
Among the 5 models, model 3 showed a nearly 89%
Ramachandaran value, by careful analysis of the residues in
the disallowed region. Structural superimposition of model 3
with its template 4LXJ, showed an RMSD value of 0.248 across
501 atom pairs (Fig. 9A). The mode of binding of lead inhibi-
tors 68 and 70 with modeled C. albicans like CYP51 was identi-
fied using molecular docking with Autodock Vina and Ligplot
(Fig. 9B–E). Since both lead compounds have an azole group
flanked by fluorobenzyl and hydrophobic side chains (Phe in
68 and Trp in 70) we have also performed hydrophobic inter-
action analysis using LIGPLOT to better characterize the inter-
actions that leads to in vitro antifungal activity. The results
revealed that proline attached to azole showed significantly
less hydrogen bonding and hydrophobic interactions and the
compounds were consequently less effective as inhibitors
(Tables 1 and 2). Tryptophan and phenylalanine based com-
pounds 68 and 70 with a common terminal p-fluorobenzyl
group (Table 1) are shown to be more effective inhibitors. The
center of the active site is positioned between the I and F
helices with heme sitting in the center of the core. Docking
studies showed that both 68 and 70 were bound very close to
the heme group in the active site pocket of CYP51 interacting
with active site residues with high binding affinities (68 =
−10.1 kcal mol−1 and 70 = −9.2 kcal mol−1). A longer side
chain of the compound compared to the fluconazole appeared
to be accommodated in the active site pocket (Fig. 9B and D).
The amino group of compound 68 formed a H-bond with the
Ser506 residue and the terminal p-fluorobenzyl group was very
close to the heme, residue Ser506 in the β-turn connecting
β4-1 and β4-2 and interacted with the heme group. A number
of hydrophobic interactions were observed with Leu376,
Phe228, Tyr132, Ile131 and Thr122 (Fig. 9B and C). The term-
inal p-fluorobenzyl group of the inhibitor was found to be
extremely close to the Tyr132 and Phe228 phenyl rings
showing a possible π–π stacking. Tyr132 has been found to
play an important role in fluconazole susceptibility of CYP51
with a fluconazole resistant isolate of C. albicans showing
mutation in Tyr132.24 Lead compound 70 similarly showed
hydrogen bonding with Asp214 and Glu194 with the side
chain of tryptophan at the entrance of the substrate binding
pocket. A number of important hydrophobic interactions were
detected with Gln309, Ser222, Tyr221, Ala218, Phe213 and
Ile197, all these residues are parts of the helix F, helix I and FG
loop in the active site pocket of the CYP51 (Fig. 9D and E).
Several residues that are important in the active site were
identified as common residues that showed interaction with
both 68 and 70 and interacted laterally and spanned the
length of the active site close to the heme group. The
N-terminal of the helix I together with the BC loop forms the
entrance of the substrate access channel and a strong inter-
action close to the substrate binding site might affect the
architecture of the active site which can distort the specificity
Fig. 7 Hemolytic assay for compounds 68 and 70 on human red blood
cells (hRBCs).
Fig. 8 Structure based sequence alignment of CYP51 from S. cerevisiae
and CYP51 of C. albicans.
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of the substrate. In the absence of the crystal structure of
CYP51 from C. albicans interacting with its natural substrate,
the interaction with the modeled CYP51 provides a rationale
for designing lead inhibitors based on the active site and
optimization of the structure activity relationship.
In vivo assessment against Galleria mellonella
The insect immune response bears many similarities to the
innate immune response of mammals and as a consequence
insects may be used to evaluate the virulence of microbial
Fig. 9 (A) Structural superimposition of model 3 with its template 4LXJ; (B) the plausible mode of binding of 68 in the active site of modeled
CYP51; (C) LIGPLOT analysis of binding of 68; (D) the possible mode of binding of 70 in the active site of modeled CYP51; (E) LIGPLOT analysis of
binding of 70. Binding energy: 68 = −10.1 kcal mol−1; 70 = −9.2 kcal mol−1.
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pathogens or assess the toxicity of antimicrobial drugs. The
larvae of G. mellonella have been used previously to assess the
toxicity of novel antifungal compounds and the results showed
a strong correlation with those obtained using mammals.25 An
in vivo study on the larvae of G. mellonella indicated significant
anticandidal potential of compounds 68 and 70. The viability
of larvae was not affected following the administration of the
compounds up to a concentration of 2.5 mg mL−1 which
showed a non-toxic behaviour towards the larvae (Fig. 10A–C).
Again, at the same concentration no significant alteration in
the haemocyte density of the larvae was found which indicated
the lack of an immune response (Fig. 10D). The administration
of a dose of 2.5 mg mL−1 of compounds 68 and 70 to the
larvae previously infected with C. albicans reduced yeast repli-
cation in vivo by 50% and 70%, respectively, as measured at
24 h (Fig. 10E).
Experimental section
Chemistry
All the chemicals and solvents (analytical grade) were purchased
from Sigma-Aldrich, USA. Thin-layer chromatographic analysis
was carried out on precoated Merck silica gel 60 F254 TLC alu-
minium sheets and the spots were visualized under UV light at
254 nm, by iodine-vapor staining or ninhydrin test. IR spectra
were recorded on an Agilent Cary 630 FT-IR spectrometer. 1H
and 13C NMR spectra were obtained in CDCl3/DMSO-d6 as a
solvent with tetramethylsilane (TMS) as an internal standard on
either a Bruker Spectrospin DPX-300 spectrometer at 300 MHz
and 75 MHz, respectively, or a Bruker Avance II 400 spectro-
meter at 400 MHz. 2D spectra (COSY and HETCOR) were
recorded on a Jeol, JNM-EXCP 400 spectrometer. Splitting pat-
terns are designated as follows: s (singlet), d (doublet),
t (triplet), q (quartet), m (multiplet) or brs (broad). 1H NMR
chemical shift (δ) values are reported in parts per million (ppm)
relative to the residual solvent (CDCl3, δ 7.26 and DMSO-d6,
δ 2.54). 13C NMR chemical shifts (δ) are reported in ppm relative
to CDCl3, δ 77.16 and DMSO-d6, δ 39.5 and coupling constants
( J) are expressed in hertz (Hz). Mass spectra were recorded on a
Waters Tandem Quadrupole Detector (TQD) integrated with an
electron spray ionization mass spectrometer and on an Agilent
RRLC MS 6320 Ion Trap spectrometer fitted with an electrospray
ionization (ESI) interface. Melting points were measured on a
digital Buchi melting point apparatus (M-560) and are uncor-
rected. The specific rotation of 41–64 was recorded on an Anton
Paar MCP-100 digital polarimeter at 20 °C using sodium D light
at a conc. of 1 g per 100 mL in ethanol. Purification of the com-
pounds was carried out by silica gel column chromatography
(230–400 mesh size, Merck, Germany) with the indicated
eluent.
General procedure for the synthesis of oximes (9–16).
Example: synthesis of 4-fluorobenzaldehyde oxime (10)
4-Fluorobenzaldehyde oxime was synthesized by reacting
4-fluorobenzaldehyde (2) (12 mmol, 1.29 mL) with
Fig. 10 Percentage viability of Galleria mellonella in the presence of
(A) 68; (B) 70; (C) DMSO; (D) haemocyte densities of larvae and
(E) fungal load assay.
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hydroxylamine hydrochloride (13 mmol, 0.90 g) in ethanol
(20 mL) and pyridine (2.0 mL) mixture under reflux for
21–23 h. After cooling, the solvent was evaporated under vacuo
and water was added to this residue. This mixture was stirred
in an ice bath until the oxime crystallizes. The solid was
filtered and washed with water. The product was crystallized
from ethanol.18
Benzaldehyde oxime (9). Colorless oil, yield 80%. Rf = 0.58
(20% EtOAc in hexane). 1H NMR (300 MHz, CDCl3) δ: 8.67
(s, 1H), 8.17 (s, 1H), 7.59–7.56 (m, 2H), 7.38 (t, J = 3.3 Hz, 3H).
IR νmax (neat)/cm
−1 3275 (O–H), 1640 (CvN) and 952 (N–O).
4-Fluorobenzaldehyde oxime (10). White solid, yield 84%.
Rf = 0.50 (20% EtOAc in hexane). Mp 86–88 °C.
1H NMR
(300 MHz, CDCl3) δ: 8.55 (s, 1H), 8.13 (s, 1H), 7.58–7.53 (m,
2H), 7.10–7.05 (m, 2H). IR νmax (neat)/cm
−1 3253 (O–H), 1689
(CvN) and 963 (N–O).
4-Chlorobenzaldehyde oxime (11). White solid, yield 89%.
Rf = 0.61 (20% EtOAc in hexane). Mp 102–104 °C.
1H NMR
(400 MHz, CDCl3) δ: 8.10 (s, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.36
(d, J = 8.5 Hz, 2H). IR νmax (neat)/cm
−1 3257 (O–H), 1659
(CvN) and 959 (N–O).
2-Chlorobenzaldehyde oxime (12). White crystalline solid,
yield 94%. Rf = 0.58 (20% EtOAc in hexane). Mp 72–74 °C.
1H NMR (300 MHz, CDCl3) δ: 8.88 (s, 1H), 8.59 (s, 1H), 7.84 (d,
J = 7.2 Hz, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.36–7.26 (m, 2H).
IR νmax (neat)/cm
−1 3242 (O–H), 1659 (CvN) and 970 (N–O).
4-Methylbenzaldehyde oxime (13). White solid, yield 90%.
Rf = 0.56 (20% EtOAc in hexane). Mp 74–76 °C.
1H NMR
(400 MHz, CDCl3) δ: 8.10 (s, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.36
(d, J = 8.4 Hz, 2H), 2.53 (s, 3H). IR νmax (neat)/cm
−1 3260
(O–H), 1659 (CvN) and 963 (N–O).
4-Methoxybenzaldehyde oxime (14). Yellow oil, yield 90%.
Rf = 0.43 (20% EtOAc in hexane).
1H NMR (400 MHz, CDCl3)
δ: 8.10 (s, 1H), 7.52 (d, J = 8.8 Hz, 2H), 6.91 (d, J = 8.8 Hz, 2H),
3.83 (s, 3H). IR νmax (neat)/cm
−1 3234 (O–H), 1611 (CvN) and
952 (N–O).
4-(Trifluoromethyl)benzaldehyde oxime (15). Light yellow
solid, yield 88%. Rf = 0.55 (20% EtOAc in hexane). Mp
88–90 °C. 1H NMR (400 MHz, CDCl3) δ: 8.17 (s, 1H), 7.70 (d,
J = 8.0 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H). IR νmax (neat)/cm
−1
3272 (O–H), 1622 (CvN) and 974 (N–O).
4-(Trifluoromethoxy)benzaldehyde oxime (16). Colourless
crystals, yield 90%. Rf = 0.61 (20% EtOAc in hexane). Mp
47–49 °C. 1H NMR (400 MHz, CDCl3) δ: 8.13 (s, 1H), 7.61 (d,
J = 8.4 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H). IR νmax (neat)/cm
−1
3267 (O–H), 1696 (CvN) and 977 (N–O).
General procedure for the synthesis of amines (17–24).
Example: synthesis of (4-fluorophenyl)methanamine (18)
To a solution of 10 (11.51 mmol, 1.6 g) in ethanol (35 mL), a
mixture of water (6.0 mL) and conc. HCl (12 mL) was added.
The reaction mixture was stirred at room temperature for
15 min and then it was allowed to cool to 0 °C. Zinc dust
(69.04 mmol, 4.38 g) was added slowly to the reaction mixture
and it was refluxed for 1 h at 80–90 °C. Progress of the reaction
was monitored by TLC. The reaction mixture was filtered and
concentrated under vacuo to yield the hydrochloride salt of
amine. The hydrochloride salt was then treated with dried
amberlyst A-21 to afford the corresponding free amine.18
Phenylmethanamine (17). Light yellow oil, yield 75%. Rf =
0.0 (40% EtOAc in hexane). 1H NMR (300 MHz, CDCl3)
δ: 7.43–7.24 (m, 5H), 3.88 (s, 2H). IR νmax (neat)/cm
−1 3367
(NH2).
(4-Fluorophenyl)methanamine (18). Light yellow oil, yield
82%. Rf = 0.0 (40% EtOAc in hexane).
1H NMR (300 MHz,
CDCl3) δ: 7.34–7.26 (m, 2H), 7.06–6.99 (m, 2H), 3.84 (s, 2H).
IR νmax (neat)/cm
−1 3372 (NH2).
(4-Chlorophenyl)methanamine (19). Light yellow oil, yield
86%. Rf = 0.0 (40% EtOAc in hexane).
1H NMR (400 MHz,
CDCl3) δ: 7.29 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.3 Hz, 2H), 3.83
(s, 2H). IR νmax (neat)/cm
−1 3365 (NH2).
(2-Chlorophenyl)methanamine (20). Light yellow oil, yield
78%. Rf = 0.0 (40% EtOAc in hexane).
1H NMR (300 MHz,
CDCl3) δ: 7.39–7.36 (m, 2H), 7.28–7.18 (m, 2H), 3.94 (s, 2H).
IR νmax (neat)/cm
−1 3372 (NH2).
(4-Methylphenyl)methanamine (21). Light yellow oil, yield
73%. Rf = 0.0 (40% EtOAc in hexane).
1H NMR (400 MHz,
CDCl3) δ: 7.20 (d, J = 7.8 Hz, 2H), 7.15 (d, J = 7.9 Hz, 2H), 3.82
(s, 2H), 2.34 (s, 3H). IR νmax (neat)/cm
−1 3382 (NH2).
(4-Methoxyphenyl)methanamine (22). Light yellow oil, yield
81%. Rf = 0.0 (40% EtOAc in hexane).
1H NMR (400 MHz,
CDCl3) δ: 7.22 (d, J = 8.5 Hz, 2H), 6.87 (d, J = 8.6 Hz, 2H), 3.79
(brs, 5H). IR νmax (neat)/cm
−1 3367 (NH2).
(4-(Trifluoromethyl)phenyl)methanamine (23). Light yellow
oil, yield 67%. Rf = 0.0 (40% EtOAc in hexane).
1H NMR
(400 MHz, CDCl3) δ: 7.91 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 7.9 Hz,
2H), 3.95 (s, 2H). IR νmax (neat)/cm
−1 3384 (NH2).
(4-(Trifluoromethoxy)phenyl)methanamine (24). Light
yellow oil, yield 71%. Rf = 0.0 (40% EtOAc in hexane).
1H NMR
(400 MHz, CDCl3) δ: 7.95 (d, J = 8.6 Hz, 2H), 7.35 (d, J = 8.3 Hz,
2H), 4.52 (s, 2H). IR νmax (neat)/cm
−1 3394 (NH2).
General procedure for the synthesis of azides (27–34).
Example: synthesis of N-(4-fluorobenzyl)-3-azidopropanamide
(28)
To a solution of 3-bromopropionic acid, 25 (19.61 mmol, 3.0 g)
in anhyd. DMF (10 mL) was added sodium azide (39.22 mmol,
2.55 g). The reaction mixture was heated at 85 °C for 3 h. The
crude reaction mixture was diluted with ethyl acetate which
was then washed with 0.1 N HCl, water and brine. The organic
layer was dried over anhyd. sodium sulphate, filtered and con-
centrated under vacuo to yield 3-azidopropionic acid, 26 which
was used directly in the next reaction without further purifi-
cation.26 The prepared azido acid (13.03 mmol, 1.5 g) was dis-
solved in acetonitrile (15 mL) and stirred at 0 °C. To this
cold solution, HOBt (15.54 mmol, 2.09 g) and EDC·HCl
(14.02 mmol, 2.69 g) were added. The reaction was stirred for
40 min and then a mixture of NMM (15.54 mmol, 1.71 mL)
and 18 (13.03 mmol, 1.28 mL) was added. The reaction
mixture was stirred overnight at room temperature. The solid
was filtered and the acetonitrile was removed under vacuo.
The residue was dissolved in 50 mL ethyl acetate, washed with
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saturated citric acid solution, 5% aq. sodium bicarbonate solu-
tion and brine. The organic layer was dried over anhyd.
sodium sulphate, filtered, evaporated and gave crude azide.
The crude product was purified by column chromatography
eluted by using a solution of ethyl acetate : hexane (4 : 6) to
yield pure azide (28).27
N-Benzyl-3-azidopropanamide (27). Yellow oil, yield 37%.
Rf = 0.48 (40% EtOAc in hexane).
1H NMR (300 MHz, CDCl3)
δ: 7.38–7.27 (m, 5H), 6.17 (brs, 1H), 4.45 (d, J = 5.7 Hz, 2H),
3.63 (t, J = 6.3 Hz, 2H), 2.45 (t, J = 6.4 Hz, 2H). 13C NMR
(75 MHz, CDCl3) δ: 171.45, 141.63, 128.94, 128.66, 127.32,
45.76, 41.56, 33.82. IR νmax (neat)/cm
−1 2093 (azide), 1644
(CvO) and 1544 (NH). MS (ESI), m/z: 205.07 [M + H]+.
N-(4-Fluorobenzyl)-3-azidopropanamide (28). Light yellow
solid, yield 49%. Rf = 0.45 (40% EtOAc in hexane). Mp
36–38 °C. 1H NMR (300 MHz, CDCl3) δ: 7.28–7.23 (m, 2H),
7.05–6.99 (m, 2H), 6.10 (brs, 1H), 4.42 (d, J = 5.7 Hz, 2H), 3.64
(t, J = 6.3 Hz, 2H), 2.45 (t, J = 6.3 Hz, 2H). 13C NMR (75 MHz,
CDCl3) δ: 169.85, 160.58, 133.80, 129.50, 115.73, 47.39, 42.99,
35.82. IR νmax (neat)/cm
−1 2086 (azide), 1641 (CvO) and 1553
(NH). MS (ESI), m/z: 223.1 [M + H]+.
N-(4-Chlorobenzyl)-3-azidopropanamide (29). Light yellow
solid, yield 36%. Rf = 0.31 (40% EtOAc in hexane). Mp
33–35 °C. 1H NMR (300 MHz, CDCl3) δ: 7.32 (d, J = 8.1 Hz, 2H),
7.23 (d, J = 7.2 Hz, 2H), 6.04 (s, 1H), 4.44 (d, J = 5.4 Hz, 2H),
3.66 (t, J = 6.0 Hz, 2H), 2.47 (t, J = 6.1 Hz, 2H). 13C NMR
(75 MHz, CDCl3) δ: 169.98, 136.56, 133.35, 129.04, 128.84,
47.39, 42.96, 35.77. IR νmax (neat)/cm
−1 2095 (azide), 1640
(CvO) and 1544 (NH). MS (ESI), mz: 239.1 [M + H]+.
N-(2-Chlorobenzyl)-3-azidopropanamide (30). Light yellow
solid, yield 39%. Rf = 0.48 (40% EtOAc in hexane). Mp
38–40 °C. 1H NMR (300 MHz, CDCl3) δ: 7.39–7.35 (m, 2H),
7.29–7.22 (m, 2H), 6.26 (brs, 1H), 4.55 (d, J = 5.7 Hz, 2H), 3.63
(t, J = 6.4 Hz, 2H), 2.46 (t, J = 6.3 Hz, 2H). 13C NMR (75 MHz,
CDCl3) δ: 169.81, 135.33, 133.63, 130.24, 129.57, 129.08,
127.17, 47.37, 41.65, 35.78. IR νmax (neat)/cm
−1 2102 (azide),
1644 (CvO) and 1551 (NH). MS (ESI), m/z: 239.1 [M + H]+.
N-(4-Methylbenzyl)-3-azidopropanamide (31). Yellow oil,
yield 53%. Rf = 0.33 (40% EtOAc in hexane).
1H NMR
(400 MHz, CDCl3) δ: 7.19–7.14 (m, 4H), 5.80 (brs, 1H), 4.42 (d,
J = 5.6 Hz, 2H), 3.66 (t, J = 6.4 Hz, 2H), 2.44 (t, J = 6.4 Hz, 2H),
2.34 (s, 3H). 13C NMR (75 MHz, CDCl3) δ: 169.58,
137.39, 134.88, 129.44, 127.84, 47.44, 43.56, 35.90, 21.08.
IR νmax (neat)/cm
−1 2102 (azide), 1618 (CvO) and 1585 (NH).
MS (ESI), m/z: 218.9 [M + H]+.
N-(4-Methoxybenzyl)-3-azidopropanamide (32). Light yellow
solid, yield 41%. Rf = 0.41 (40% EtOAc in hexane). Mp
58–60 °C. 1H NMR (300 MHz, CDCl3) δ: 7.14 (d, J = 8.4 Hz, 2H),
6.80 (d, J = 8.7 Hz, 2H), 5.77 (brs, 1H), 4.32 (d, J = 5.4 Hz, 2H),
3.73 (s, 3H), 3.58 (t, J = 6.4 Hz, 2H), 2.36 (t, J = 6.4 Hz, 2H).
13C NMR (75 MHz, CDCl3) δ: 169.85, 160.58, 133.80, 129.50,
115.73, 57.04, 47.39, 42.99, 35.82. IR νmax (neat)/cm
−1 2091
(azide), 1637 (CvO) and 1559 (NH). MS (ESI), m/z: 234.9
[M + H]+.
N-(4-(Trifluoromethyl)benzyl)-3-azidopropanamide (33).
Light yellow oil, yield 56%. Rf = 0.43 (40% EtOAc in hexane).
1H NMR (400 MHz, CDCl3) δ: 7.60 (d, J = 8.0 Hz, 2H), 7.40 (d,
J = 7.7 Hz, 2H), 5.96 (brs, 1H), 4.53 (d, J = 5.8 Hz, 2H), 3.68 (t,
J = 6.2 Hz, 2H), 2.48 (t, J = 6.2 Hz, 2H). 13C NMR (75 MHz,
CDCl3) δ: 170.01, 142.05, 129.67, 127.87, 125.71, 122.24, 47.38,
43.18, 35.86. IR νmax (neat)/cm
−1 2107 (azide), 1654 (CvO) and
1547 (NH). MS (ESI), m/z: 272.9 [M + H]+, 271.1 [M − H]−.
N-(4-(Trifluoromethoxy)benzyl)-3-azidopropanamide (34).
Yellow oil, yield 45%. Rf = 0.27 (40% EtOAc in hexane).
1H NMR (400 MHz, CDCl3) δ: 7.32 (d, J = 8.4 Hz, 2H), 7.19 (d,
J = 8.2 Hz, 2H), 5.90 (brs, 1H), 4.46 (d, J = 7.1 Hz, 2H), 3.67 (t,
J = 6.2 Hz, 2H), 2.46 (t, J = 6.3 Hz, 2H). 13C NMR (75 MHz,
CDCl3) δ: 169.85, 158.72, 134.58, 129.50, 123.53, 115.76, 47.39,
42.99, 35.82. IR νmax (neat)/cm
−1 2102 (azide), 1652 (CvO) and
1547 (NH). MS (ESI), m/z: 289.45 [M + H]+.
General procedure for the synthesis of propargyl ester of
boc-protected alkynes (38–40). Example: synthesis of propargyl
ester of boc-L-phenylalanine (38)
Boc-protected L-phenylalanine (11.31 mmol, 3.0 g) was dis-
solved in anhyd. DMF (10 mL) and the solution was allowed to
cool to 0 °C. Anhyd. potassium carbonate (16.96 mmol, 2.34 g)
was added to this cold solution and stirred for 15 min.
Propargyl bromide (11.31 mmol, 1.26 mL, 80 wt% in toluene)
was added dropwise to the mixture and stirred at 0 °C for 1 h.
The reaction mixture was allowed to attain room temperature.
After removal of DMF under vacuo, the residue was dissolved
in ethyl acetate. The organic layer was washed with saturated
citric acid solution, water and brine which was dried over
anhyd. sodium sulphate and concentrated. The crude product
was then purified by column chromatography eluted by using
ethyl acetate : hexane (2 : 8) to yield pure alkyne (38).28
Propargyl ester of boc-L-phenylalanine (38). Light yellow oil,
yield 87%. Rf = 0.52 (20% EtOAc in hexane).
1H NMR
(300 MHz, CDCl3) δ: 7.34–7.26 (m, 3H), 7.19–7.17 (m, 2H), 4.97
(d, J = 7.5 Hz, 1H), 4.82–4.64 (m, 3H), 3.20–3.06 (m, 2H), 2.53
(s, 1H), 1.43 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 171.16,
155.07, 135.70, 129.41, 128.61, 127.13, 80.06, 75.47, 54.31,
52.65, 38.10, 28.28. IR νmax (neat)/cm
−1 3365 (uCH), 2129
(CuC), 1762 (CvO, ester), 1687 (CvO, amide) and 1510 (NH).
MS (ESI), m/z: 326.2 [M + Na]+, 629.4 [2M + Na]+.
Propargyl ester of boc-L-proline (39). Light yellow oil, yield
85%. Rf = 0.64 (20% EtOAc in hexane).
1H NMR (300 MHz,
CDCl3) δ: 4.78–4.69 (m, 2H), 4.29–4.25 (m, 1H), 3.58–3.40 (m,
2H), 2.48 (s, 1H), 2.26–2.23 (m, 1H), 2.05–1.91 (m, 3H), 1.42 (s,
9H). 13C NMR (75 MHz, CDCl3) δ: 172.42, 153.70, 80.06, 75.11,
58.91, 52.23, 46.30, 30.79, 28.28, 23.61. IR νmax (neat)/cm
−1
3246 (uCH), 2129 (CuC), 1754 (CvO, ester) and 1693 (CvO,
amide). MS (ESI), m/z: 254.4 [M + H]+.
Propargyl ester of boc-L-tryptophan (40). Light yellow solid,
yield 88%. Rf = 0.31 (20% EtOAc in hexane). Mp 95–96 °C.
1H
NMR (300 MHz, CDCl3) δ: 8.17 (s, 1H), 7.60 (d, J = 7.8 Hz, 1H),
7.38 (d, J = 7.8 Hz, 1H), 7.21–7.12 (m, 2H), 7.07 (s, 1H), 5.08 (d,
J = 8.1 Hz, 1H), 4.77–4.63 (m, 3H), 3.35–3.33 (m, 2H), 2.50 (s,
1H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 171.54, 155.24,
136.12, 127.71, 122.95, 122.24, 119.69, 118.76, 111.20, 109.92,
79.99, 75.37, 54.23, 52.65, 28.32, 27.76. IR νmax (neat)/cm
−1
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3397 (uCH), 2147 (CuC), 1736 (CvO, ester), 1698 (CvO,
amide) and 1503 (NH). MS (ESI), m/z: 365.09 [M + Na]+, 707.4
[2M + Na]+.
Synthesis of boc-protected triazole–amino acid hybrids
(41–64). Example: synthesis of (R)-(1-(3-(4-fluorobenzyl-
amino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methyl 2-[(tert-
butoxycarbonyl)amino]-3-phenylpropanoate (44)
Azide 28 (1.35 mmol, 0.3 g) and alkyne 38 (1.35 mmol, 0.41 g)
were dissolved in tert-butanol (4.0 mL) and H2O (8.0 mL). The
copper sulphate, CuSO4·5H2O (0.013 mmol, 0.033 g) and
sodium ascorbate (0.067 mmol, 0.013 g) were added and the
reaction mixture was stirred at room temperature. Progress of
the reaction was monitored by TLC. After completion of the
reaction, the content of the reaction was washed with brine
and the compound was extracted with ethyl acetate, dried over
anhyd. sodium sulphate and concentrated. The product was
purified by column chromatography eluted with ethyl acetate :
hexane (3 : 7) to yield the pure product in quantitative yield.29
(R)-(1-(3-(Benzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methyl
2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate (41). Off
white solid, yield 86%. Rf = 0.76 (10% MeOH in DCM). Mp
93–95 °C. [α]20D = −28.00.
1H NMR (300 MHz, CDCl3) δ: 7.50
(s, 1H), 7.26–7.15 (m, 7H), 7.10 (d, J = 7.5 Hz, 2H), 6.99–6.97
(m, 1H), 5.91 (brs, 1H), 5.14 (s, 2H), 4.88 (d, J = 7.2 Hz, 1H),
4.62 (t, J = 5.6 Hz, 2H), 4.47–4.45 (m, 1H), 4.32 (d, J = 5.7 Hz,
2H), 3.02–2.95 (m, 2H), 2.78 (t, J = 6.3 Hz, 2H), 1.33 (s, 9H).
13C NMR (75 MHz, CDCl3) δ: 171.65, 168.99, 155.08, 142.07,
137.79, 135.82, 129.33, 128.69, 128.50, 127.69, 127.59, 126.99,
125.09, 80.03, 58.23, 54.40, 46.25, 43.67, 38.05, 36.32, 28.28.
IR νmax (neat)/cm
−1 3078 (CH), 1598 (CvC) and 1460 (NvN).
MS (ESI), m/z: 508.3 [M + H]+.
(R)-(1-(3-(Benzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)
methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylate (42).
Light yellow oil, yield 84%. Rf = 0.84 (10% MeOH in DCM).
[α]20D = −48.00.
1H NMR (300 MHz, CDCl3) δ: 7.71 (s, 1H),
7.31–7.19 (m, 5H), 6.04 (brs, 1H), 5.26–5.21 (m, 2H), 4.73–4.71
(m, 2H), 4.41 (s, 2H), 4.25–4.16 (m, 1H), 3.53–3.39 (m, 2H),
2.89–2.84 (m, 2H), 2.21–2.15 (m, 1H), 1.94–1.86 (m, 3H), 1.45
(s, 9H). 13C NMR (75 MHz, CDCl3) δ: 173.02, 168.97, 154.44,
142.91, 137.75, 128.70, 127.69, 124.98, 79.94, 58.99, 57.94,
46.63, 43.66, 36.58, 30.79, 29.79, 28.41, 24.33. IR νmax (neat)/
cm−1 3067 (CH), 1549 (CvC) and 1454 (NvN). MS (ESI), m/z:
358.3 [M + H − Boc]+, 458.4 [M + H]+.
(R)-(1-(3-(Benzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)methyl
2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)propanoate (43).
Light yellow solid, yield 92%. Rf = 0.67 (10% MeOH in DCM).
Mp 68–70 °C. [α]20D = −20.00.
1H NMR (300 MHz, CDCl3) δ: 8.74
(s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 7.8 Hz, 1H),
7.26–7.19 (m, 4H), 7.12–6.99 (m, 4H), 6.46 (s, 1H), 6.13 (s, 1H),
5.23–5.16 (m, 1H), 5.04–5.00 (m, 2H), 4.60–4.44 (m, 3H),
4.32 (t, J = 6.0 Hz, 2H), 3.16–3.14 (m, 2H), 2.90–2.77 (m, 2H),
1.37 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 172.12, 169.48,
155.24, 142.43, 137.63, 136.09, 128.74, 127.61, 127.51, 124.99,
123.29, 121.91, 119.45, 118.75, 111.34, 109.41, 79.97, 58.23,
54.52, 46.11, 43.71, 35.64, 28.35, 28.06. IR νmax (neat)/cm
−1
3060 (CH), 1525 (CvC) and 1458 (NvN). MS (ESI), m/z: 547.3
[M + H]+.
(R)-(1-(3-(4-Fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate
(44). Creamish solid, yield 89%. Rf = 0.77 (10% MeOH in
DCM). Mp 88–90 °C. [α]20D = −4.00.
1H NMR (300 MHz, CDCl3)
δ: 7.57 (s, 1H), 7.22 (m, 3H), 7.14 (brs, 2H), 7.06 (brs, 2H),
7.00–6.95 (m, 2H), 6.36 (brs, 1H), 5.19 (s, 2H), 4.96 (brs, 1H),
4.67 (brs, 2H), 4.51 (m, 1H), 4.35 (brs, 2H), 3.04 (m, 2H), 2.86
(brs, 2H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 171.66,
168.97, 160.77, 155.33, 142.18, 140.27, 135.81, 133.66, 129.47,
128.52, 127.01, 125.03, 115.39, 80.07, 58.23, 54.44, 46.23,
42.96, 38.05, 36.30, 28.27. IR νmax (neat)/cm
−1 3057 (CH), 1514
(CvC) and 1458 (NvN). MS (ESI), m/z: 526.1 [M + H]+, 548.1
[M + Na]+.
(R)-(1-(3-(4-Fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylate (45).
Light yellow oil, yield 80%. Rf = 0.70 (10% MeOH in DCM).
[α]20D = −44.00.
1H NMR (300 MHz, CDCl3) δ: 7.73 (d, J =
11.1 Hz, 1H), 7.20–7.12 (m, 2H), 7.04–6.97 (m, 2H), 6.55 (brs,
1H), 5.33–5.22 (m, 2H), 4.79–4.66 (m, 2H), 4.39–4.37 (m, 2H),
4.26–4.23 (m, 1H), 3.52–3.39 (m, 2H), 2.92–2.85 (m, 2H),
2.21–1.84 (m, 4H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3)
δ: 172.99, 169.24, 153.67, 142.68, 138.75, 134.33, 129.39,
124.95, 115.37, 79.83, 58.92, 46.63, 46.28, 42.59, 35.96, 30.76,
28.39, 23.59. IR νmax (neat)/cm
−1 3075 (CH), 1512 (CvC) and
1452 (NvN). MS (ESI), m/z: 376.05 [M + H − Boc]+, 476.04
[M + H]+, 498.2 [M + Na]+.
(R)-(1-(3-(4-Fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)pro-
panoate (46). Light yellow solid, yield 90%. Rf = 0.71 (10%
MeOH in DCM). Mp 62–64 °C. [α]20D = −20.00.
1H NMR
(300 MHz, CDCl3) δ: 8.88 (s, 1H, NH), 7.53 (d, J = 7.5 Hz, 1H,
Ar–H), 7.35 (d, J = 8.1 Hz, 1H, Ar–H), 7.17–7.05 (m, 5H, Ar–H),
6.96 (t, J = 8.6 Hz, 2H, Ar–H), 6.56–6.52 (m, 2H, Ar–H, NH),
5.25–5.21 (m, 1H, NH), 5.14–5.05 (m, 2H, OCH2), 4.65–4.49 (m,
3H, CH, CH2), 4.33–4.32 (m, 2H, CH2), 3.23 (brs, 2H, CH2),
2.94–2.82 (m, 2H, CH2), 1.43 (s, 9H, Boc).
13C NMR (75 MHz,
CDCl3) δ: 172.11, 169.45, 163.82, 155.26, 142.52, 136.09,
133.43, 129.31, 127.74, 125.01, 123.22, 121.97, 119.49, 118.76,
115.69, 111.29, 109.48, 79.98, 58.21, 54.51, 46.08, 43.01, 35.59,
28.33, 27.97. IR νmax (neat)/cm
−1 3080 (CH), 1512 (CvC) and
1460 (NvN). MS (ESI), m/z: 565.3 [M + H]+.
(R)-(1-(3-(4-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate
(47). White solid, yield 88%. Rf = 0.72 (10% MeOH in DCM).
Mp 98–100 °C. [α]20D = −16.00.
1H NMR (300 MHz, CDCl3)
δ: 7.56 (s, 1H), 7.27–7.22 (m, 5H), 7.10–7.04 (m, 4H), 6.60 (brs,
1H), 5.18 (s, 2H), 4.98 (d, J = 7.8 Hz, 1H), 4.68–4.63 (m, 2H),
4.50–4.46 (m, 1H), 4.34 (d, J = 5.7 Hz, 2H), 3.08–2.98 (m, 2H),
2.87 (t, J = 6.3 Hz, 2H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3)
δ: 171.66, 169.09, 155.13, 142.17, 136.45, 135.79, 133.32,
129.31, 129.04, 128.78, 128.52, 127.02, 125.07, 80.06, 58.20,
54.43, 46.25, 42.93, 38.01, 36.26, 28.27. IR νmax (neat)/cm
−1
3067 (CH), 1521 (CvC) and 1462 (NvN). MS (ESI), m/z: 542.5
[M + H]+.
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(R)-(1-(3-(4-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylate (48).
Colorless oil, yield 87%. Rf = 0.67 (10% MeOH in DCM). [α]20D =
−44.00. 1H NMR (300 MHz, CDCl3) δ: 7.62 (s, 1H), 7.19 (d, J =
9.0 Hz, 2H), 7.05–6.98 (m, 2H), 6.59 (brs, 1H), 5.17–5.10 (m,
2H), 4.68–4.51 (m, 2H), 4.29–4.24 (m, 2H), 4.20–4.16 (m, 1H),
3.41–3.27 (m, 2H), 2.84–2.74 (m, 2H), 2.11–1.98 (m, 2H),
1.86–1.77 (m, 2H), 1.35–1.26 (m, 9H). 13C NMR (75 MHz,
CDCl3) δ: 173.02, 169.15, 154.46, 143.01, 136.57, 133.31,
129.05, 128.76, 125.02, 79.97, 58.99, 58.06, 46.67, 42.89, 36.59,
30.78, 29.78, 28.41, 24.34. IR νmax (neat)/cm
−1 3089 (CH), 1547
(CvC) and 1495 (NvN). MS (ESI), m/z: 392.5 [M + H − Boc]+,
492.4 [M + H]+.
(R)-(1-(3-(4-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)pro-
panoate (49). Light yellow solid, yield 87%. Rf = 0.73 (10%
MeOH in DCM). Mp 70–72 °C. [α]20D = −20.00.
1H NMR
(300 MHz, CDCl3) δ: 8.88 (s, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.34
(d, J = 8.1 Hz, 1H), 7.26–7.22 (m, 2H), 7.18–7.13 (m, 2H),
7.10–7.03 (m, 3H), 6.65 (brs, 1H), 6.53 (s, 1H), 5.25–5.20 (m,
1H), 5.09–5.04 (m, 2H), 4.64–4.48 (m, 3H), 4.31 (d, J = 6.0 Hz,
2H), 3.23–3.21 (m, 2H), 2.94–2.82 (m, 2H), 1.43 (s, 9H).
13C NMR (75 MHz, CDCl3) δ: 172.12, 169.56, 155.26, 142.51,
136.26, 136.08, 133.33, 128.86, 128.80, 127.72, 125.04, 123.24,
121.96, 119.49, 118.75, 111.31, 109.45, 79.99, 58.19, 54.50,
46.10, 42.99, 35.55, 28.33, 27.97. IR νmax (neat)/cm
−1 3083
(CH), 1514 (CvC) and 1462 (NvN). MS (ESI), m/z: 579.2
[M − H]−, 581.1 [M + H]+.
(R)-(1-(3-(2-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate
(50). White solid, yield 84%. Rf = 0.73 (10% MeOH in DCM).
Mp 118–120 °C. [α]20D = −16.00.
1H NMR (300 MHz, CDCl3)
δ: 7.48 (s, 1H), 7.29–7.13 (m, 7H), 6.99–6.97 (m, 2H), 6.05 (brs,
1H), 5.13 (s, 2H), 4.89 (d, J = 7.5 Hz, 1H), 4.61 (t, J = 5.8 Hz,
2H), 4.48–4.47 (m, 1H), 4.41 (d, J = 5.7 Hz, 2H), 3.05–2.90 (m,
2H), 2.78 (t, J = 6.2 Hz, 2H), 1.33 (s, 9H). 13C NMR (75 MHz,
CDCl3) δ: 171.60, 168.97, 155.28, 143.42, 137.44, 135.82,
133.62, 130.05, 129.52, 129.29, 129.07, 128.45, 127.05, 126.94,
125.33, 79.98, 58.20, 54.31, 46.10, 41.60, 37.98, 36.24, 28.23.
IR νmax (neat)/cm
−1 3062 (CH), 1521 (CvC) and 1445 (NvN).
MS (ESI), m/z: 542.1 [M + H]+.
(R)-(1-(3-(2-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylate (51).
Colorless oil, yield 83%. Rf = 0.77 (10% MeOH in DCM). [α]20D =
−48.00. 1H NMR (300 MHz, CDCl3) δ: 7.69 (d, J = 7.5 Hz, 1H),
7.39–7.23 (m, 4H), 6.43 (brs, 1H), 5.26–5.20 (m, 2H), 4.78–4.63
(m, 2H), 4.50 (d, J = 5.4 Hz, 2H), 4.26–4.23 (m, 1H), 3.55–3.39
(m, 2H), 2.91–2.83 (m, 2H), 2.21–2.10 (m, 1H), 1.95–1.84 (m,
3H), 1.45 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 173.21, 167.98,
154.44, 142.91, 137.75, 133.45, 128.70, 126.98, 124.98, 79.94,
58.10, 57.99, 46.44, 43.66, 36.58, 30.79, 29.79, 28.41, 23.60.
IR νmax (neat)/cm
−1 3073 (CH), 1544 (CvC) and 1447 (NvN).
MS (ESI), m/z: 492.3 [M + H]+.
(R)-(1-(3-(2-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)pro-
panoate (52). Light yellow solid, yield 88%. Rf = 0.41 (10%
MeOH in DCM). Mp 58–62 °C. [α]20D = −16.00.
1H NMR
(300 MHz, CDCl3) δ: 8.83 (s, 1H), 7.56 (d, J = 7.8 Hz, 1H),
7.41–7.35 (m, 3H), 7.29–7.08 (m, 5H), 6.60 (s, 1H), 6.36 (brs,
1H), 5.29–5.25 (m, 1H), 5.14–5.09 (m, 2H), 4.68–4.54 (m, 3H),
4.49 (brs, 2H), 3.26–3.19 (m, 2H), 2.95–2.88 (m, 2H), 1.46 (s,
9H). 13C NMR (75 MHz, CDCl3) δ: 172.12, 169.54, 155.24,
142.43, 136.07, 134.96, 133.48, 129.73, 129.59, 129.09, 127.75,
127.11, 125.02, 123.28, 121.92, 119.46, 118.78, 111.32, 109.42,
79.96, 58.24, 54.48, 46.02, 41.70, 35.53, 28.35, 28.02. IR νmax
(neat)/cm−1 3067 (CH), 1514 (CvC) and 1447 (NvN). MS (ESI),
m/z: 581.3 [M + H]+.
(R)-(1-(3-(4-Methylbenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate
(53). Creamish solid, yield 90%. Rf = 0.63 (10% MeOH in
DCM). Mp 105–107 °C. [α]20D = −16.00.
1H NMR (300 MHz,
CDCl3) δ: 7.57 (s, 1H), 7.26–7.21 (m, 3H), 7.11–7.04 (m, 6H),
6.34 (brs, 1H), 5.21 (s, 2H), 4.99 (d, J = 7.8 Hz, 1H), 4.65 (t, J =
6.3 Hz, 2H), 4.56–4.50 (m, 1H), 4.33 (d, J = 5.7 Hz, 2H),
3.11–2.96 (m, 2H), 2.83 (t, J = 6.3 Hz, 2H), 2.31 (s, 3H), 1.40 (s,
9H). 13C NMR (75 MHz, CDCl3) δ: 171.64, 168.88, 155.09,
142.05, 137.32, 135.83, 134.74, 129.36, 128.49, 127.72, 126.99,
125.08, 80.02, 58.24, 54.40, 46.23, 43.45, 38.05, 36.35, 28.27,
21.07. IR νmax (neat)/cm
−1 3067 (CH), 1521 (CvC) and 1462
(NvN). MS (ESI), m/z: 522.2 [M + H]+.
(R)-(1-(3-(4-Methylbenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylate (54).
Colorless oil, yield 83%. Rf = 0.67 (10% MeOH in DCM). [α]20D =
−48.00. 1H NMR (300 MHz, CDCl3) δ: 7.70 (s, 1H), 7.12–7.03
(m, 4H), 6.45 (brs, 1H), 5.19 (m, 2H), 4.69–4.64 (m, 2H),
4.34–4.32 (m, 2H), 4.23–4.19 (m, 1H), 3.51–3.37 (m, 2H),
2.87–2.79 (m, 2H), 2.31 (s, 3H), 2.19–2.12 (m, 2H), 1.95–1.81
(m, 3H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 172.99,
168.94, 154.42, 142.83, 137.26, 134.86, 129.32, 127.70, 124.97,
79.92, 58.98, 58.08, 46.62, 43.38, 36.52, 30.78, 29.78, 28.40,
24.33, 21.05. IR νmax (neat)/cm
−1 3089 (CH), 1547 (CvC) and
1454 (NvN). MS (ESI), m/z: 358.3 [M + H − Boc]+, 471.99
[M + H]+, 494.13 [M + Na]+.
(R)-(1-(3-(4-Methylbenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)pro-
panoate (55). Light yellow solid, yield 83%. Rf = 0.67 (10%
MeOH in DCM). Mp 68–70 °C. [α]20D = −16.00.
1H NMR
(400 MHz, CDCl3) δ: 8.75 (s, 1H), 7.55 (d, J = 7.7 Hz, 1H), 7.38
(d, J = 7.6 Hz, 1H), 7.19–6.99 (m, 7H), 6.56 (s, 1H), 5.98 (brs,
1H), 5.29–5.26 (m, 1H), 5.13–5.09 (m, 2H), 4.66–4.56 (m, 3H),
4.40–4.34 (m, 2H), 3.25–3.19 (m, 2H), 2.95–2.84 (m, 2H), 2.33
(s, 3H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3) δ: 172.13,
169.44, 155.24, 142.42, 141.22, 137.35, 136.09, 134.58, 129.39,
127.75, 125.01, 123.32, 121.90, 119.44, 118.76, 111.37, 109.36,
79.97, 58.23, 54.54, 46.11, 43.49, 35.63, 28.35, 28.06, 21.07.
IR νmax (neat)/cm
−1 3089 (CH), 1514 (CvC) and 1462 (NvN).
MS (ESI), m/z: 559.15 [M − H]−, 561.65 [M + H]+.
(R)-(1-(3-(4-Methoxybenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoate
(56). Creamish solid, yield 95%. Rf = 0.76 (10% MeOH in
DCM). Mp 108–110 °C. [α]20D = −16.00.
1H NMR (400 MHz,
CDCl3) δ: 7.60 (s, 1H), 7.24–7.22 (m, 3H), 7.10 (d, J = 8.5 Hz,
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2H), 7.06–7.04 (m, 2H), 6.84 (d, J = 8.5 Hz, 2H), 5.79 (brs, 1H),
5.22 (s, 2H), 4.95 (d, J = 7.8 Hz, 1H), 4.74–4.67 (m, 2H),
4.55–4.53 (m, 1H), 4.31 (d, J = 5.6 Hz, 2H), 3.78 (s, 3H),
3.11–2.99 (m, 2H), 2.83 (t, J = 6.2 Hz, 2H), 1.40 (s, 9H). 13C
NMR (75 MHz, CDCl3) δ: 171.64, 168.82, 159.09, 155.09,
142.08, 135.83, 129.82, 129.34, 129.11, 128.50, 126.99, 125.06,
114.09, 80.02, 58.26, 55.29, 54.39, 46.23, 43.19, 38.04, 36.36,
28.27. IR νmax (neat)/cm
−1 3070 (CH), 1514 (CvC) and 1458
(NvN). MS (ESI), m/z: 538.1 [M + H]+.
(R)-(1-(3-(4-Methoxybenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylate (57).
Light yellow oil, yield 86%. Rf = 0.71 (10% MeOH in DCM).
[α]20D = −44.00.
1H NMR (400 MHz, CDCl3) δ: 7.69 (d, J = 4.5 Hz,
1H), 7.16–7.08 (m, 2H), 6.86–6.83 (m, 2H), 6.10 (brs, 1H),
5.26–5.21 (m, 2H), 4.73–4.66 (m, 2H), 4.33–4.32 (m, 2H),
4.24–4.12 (m, 1H), 3.79 (s, 3H), 3.52–3.45 (m, 2H), 2.86–2.78
(m, 2H), 1.96–1.82 (m, 2H), 1.70 (m, 2H), 1.43 (s, 9H).
13C NMR (75 MHz, CDCl3) δ: 173.03, 168.89, 159.10, 154.42,
142.92, 129.95, 129.11, 124.97, 114.08, 79.92, 58.99, 58.12,
55.29, 46.63, 43.17, 36.59, 30.79, 29.78, 28.41, 24.34. IR νmax
(neat)/cm−1 3095 (CH), 1514 (CvC) and 1462 (NvN). MS (ESI),
m/z: 388.2 [M + H − Boc]+, 488.08 [M + H]+.
(R)-(1-(3-(4-Methoxybenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-(1H-indol-3-yl)pro-
panoate (58). Light yellow solid, yield 92%. Rf = 0.67 (10%
MeOH in DCM). Mp 72–74 °C. [α]20D = −20.00.
1H NMR
(400 MHz, CDCl3) δ: 8.84 (s, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.38
(d, J = 8.0 Hz, 1H), 7.19–7.15 (m, 2H), 7.10–7.07 (m, 3H), 6.83
(d, J = 8.6 Hz, 2H), 6.52 (s, 1H), 6.02 (brs, 1H), 5.29–5.26 (m,
1H), 5.12–5.09 (m, 2H), 4.67–4.52 (m, 3H), 4.34–4.30 (m, 2H),
3.78 (s, 3H), 3.26–3.20 (m, 2H), 2.96–2.83 (m, 2H), 1.44 (s, 9H).
13C NMR (75 MHz, CDCl3) δ: 172.12, 169.36, 159.07, 155.24,
142.43, 136.09, 129.66, 128.93, 127.76, 125.00, 123.31, 121.91,
119.44, 118.76, 114.10, 111.35, 109.39, 79.95, 58.23, 55.29,
54.54, 46.10, 43.23, 35.61, 28.35, 28.02. IR νmax (neat)/cm
−1
3067 (CH), 1514 (CvC) and 1460 (NvN). MS (ESI), m/z: 575.37
[M − H]−, 577.10 [M + H]+.
(R)-(1-(3-(4-Trifluoromethylbenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-phe-
nylpropanoate (59). White solid, yield 94%. Rf = 0.53 (10%
MeOH in DCM). Mp 103–105 °C. [α]20D = −20.00.
1H NMR
(400 MHz, CDCl3) δ: 7.57–7.55 (m, 3H), 7.33–7.22 (m, 4H),
7.05–7.04 (m, 2H), 6.19 (brs, 1H), 5.22 (s, 2H), 4.94 (d, J =
7.2 Hz, 1H), 4.75–4.68 (m, 2H), 4.49–4.47 (m, 1H), 4.43 (d, J =
5.7 Hz, 2H), 3.09–2.98 (m, 2H), 2.89 (brs, 2H), 1.39 (s, 9H). 13C
NMR (75 MHz, CDCl3) δ: 171.68, 169.22, 155.14, 142.24,
141.96, 135.76, 129.30, 128.53, 127.82, 127.04, 125.62, 125.57,
125.09, 80.09, 58.19, 54.43, 46.23, 43.11, 37.96, 36.27, 28.26.
IR νmax (neat)/cm
−1 3032 (CH), 1529 (CvC) and 1447 (NvN).
MS (ESI), m/z: 576.1 [M + H]+.
(R)-(1-(3-(4-Trifluoromethylbenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-
carboxylate (60). Colorless oil, yield 94%. Rf = 0.48 (10%
MeOH in DCM). [α]20D = −40.00.
1H NMR (300 MHz, CDCl3)
δ: 7.52 (d, J = 7.8 Hz, 1H), 7.35–7.07 (m, 4H), 6.76 (brs, 1H),
5.29–5.05 (m, 2H), 4.61–4.56 (m, 2H), 4.53 (d, J = 6.0 Hz, 2H),
4.25–4.16 (m, 1H), 3.21 (brs, 2H), 3.03–2.86 (m, 2H), 2.21–2.15
(m, 1H), 1.94–1.86 (m, 3H), 1.42 (s, 9H). 13C NMR (75 MHz,
CDCl3) δ: 172.12, 169.72, 155.27, 142.58, 136.06, 127.65,
125.61, 123.18, 119.50, 111.29, 80.01, 58.16, 54.48, 46.09,
43.14, 35.51, 29.70, 28.32, 27.91. IR νmax (neat)/cm
−1 3082
(CH), 1546 (CvC) and 1452 (NvN). MS (ESI), m/z: 426.05
[M + H − Boc]+, 526.04 [M + H]+.
(R)-(1-(3-(4-Trifluoromethylbenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-(1H-
indol-3-yl)propanoate (61). Light yellow solid, yield 76%. Rf =
0.47 (10% MeOH in DCM). Mp 55–60 °C. [α]20D = −20.00.
1H NMR (400 MHz, CDCl3) δ: 8.71 (s, 1H), 7.54 (t, J = 8.0 Hz,
3H), 7.35 (d, J = 8.1 Hz, 1H), 7.24–7.14 (m, 3H), 7.08 (t, J = 7.4
Hz, 2H), 6.50 (s, 1H), 6.28 (brs, 1H), 5.29–5.26 (m, 1H),
5.14–5.09 (m, 2H), 4.63–4.52 (m, 3H), 4.43 (s, 2H), 3.23 (s, 2H),
2.99–2.88 (m, 2H), 1.43 (s, 9H). 13C NMR (75 MHz, CDCl3)
δ: 172.99, 169.43, 154.47, 153.76, 143.02, 142.26, 137.93,
136.29, 127.79, 126.04, 125.47, 125.08, 124.50, 121.87, 119.23,
118.45, 111.21, 109.34, 79.98, 58.96, 57.99, 46.66, 42.99, 36.54,
30.72, 28.37. IR νmax (neat)/cm
−1 3091 (CH), 1510 (CvC) and
1460 (NvN). MS (ESI), m/z: 613.27 [M − H]−, 615.13 [M + H]+.
(R)-(1-(3-(4-Trifluoromethoxybenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-[(tert-butoxycarbonyl)amino]-3-phe-
nylpropanoate (62). Light yellow solid, yield 89%. Rf = 0.69
(10% MeOH in DCM). Mp 110–113 °C. [α]20D = −24.00.
1H NMR
(300 MHz, CDCl3) δ: 7.49 (s, 1H), 7.28–7.21 (m, 5H), 7.09–6.89
(m, 4H), 5.91 (brs, 1H), 5.23 (s, 2H), 4.67 (d, J = 7.4 Hz, 1H),
4.71 (t, J = 5.8 Hz, 2H), 4.48–4.46 (m, 1H), 4.41 (d, J = 5.4 Hz,
2H), 3.12–3.01 (m, 2H), 2.82 (t, J = 6.8 Hz, 2H), 1.40 (s, 9H).
13C NMR (75 MHz, CDCl3) δ: 171.82, 169.78, 156.24, 142.63,
137.89, 137.09, 135.86, 128.54, 127.61, 127.32, 124.78, 123.29,
121.56, 115.45, 79.32, 58.51, 54.71, 46.31, 43.71, 38.67, 35.55,
28.35. IR νmax (neat)/cm
−1 3067 (CH), 1533 (CvC) and 1447
(NvN). MS (ESI), m/z: 592.3 [M + H]+.
(R)-(1-(3-(4-Trifluoromethoxybenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 1-(tert-butoxycarbonyl)pyrrolidine-2-
carboxylate (63). Light yellow oil, yield 89%. Rf = 0.65 (10%
MeOH in DCM). [α]20D = −44.00.
1H NMR (300 MHz, CDCl3)
δ: 7.71 (d, J = 9.7 Hz, 1H), 7.24–7.16 (m, 2H), 7.02–6.95 (m, 2H),
6.43 (brs, 1H), 5.41–5.28 (m, 2H), 4.75–4.68 (m, 2H), 4.42–4.39
(m, 2H), 4.28–4.25 (m, 1H), 3.67–3.47 (m, 2H), 2.81–2.76 (m,
2H), 2.12–1.89 (m, 4H), 1.39–1.32 (m, 9H). 13C NMR (75 MHz,
CDCl3) δ: 173.12, 168.12, 158.23, 154.30, 142.73, 139.32,
135.03, 129.02, 124.82, 121.67, 114.23, 79.78, 58.23, 46.85,
46.30, 42.80, 35.67, 30.56, 28.23, 23.70. IR νmax (neat)/cm
−1
3056 (CH), 1544 (CvC) and 1460 (NvN). MS (ESI), m/z: 542.3
[M + H]+.
(R)-(1-(3-(4-Trifluoromethoxybenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-(tert-butoxycarbonyl)-3-(1H-indol-3-
yl)propanoate (64). Light yellow solid, yield 89%. Rf = 0.62
(10% MeOH in DCM). Mp 70–72 °C. [α]20D = −24.00.
1H NMR
(300 MHz, CDCl3) δ: 8.92 (s, 1H), 7.56 (d, J = 7.0 Hz, 1H),
7.32–7.28 (m, 4H), 7.14–7.02 (m, 5H), 6.43 (s, 1H), 6.21 (brs,
1H), 5.46–5.41 (m, 1H), 5.14–5.03 (m, 2H), 4.65–4.51 (m, 3H),
4.23 (m, 2H), 3.19–3.12 (m, 2H), 2.87–2.72 (m, 2H), 1.43 (s,
9H). 13C NMR (75 MHz, CDCl3) δ: 171.88, 169.57, 156.12,
Paper Organic & Biomolecular Chemistry
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142.87, 137.51, 136.24, 128.54, 127.78, 127.21, 124.73, 122.89,
121.72, 119.03, 118.56, 111.47, 109.25, 79.89, 58.21, 54.76,
46.23, 43.53, 36.03, 28.42. IR νmax (neat)/cm
−1 3078 (CH), 1510
(CvC) and 1460 (NvN). MS (ESI), m/z: 630.1 [M + H]+.
Deprotection of boc-protected triazole–amino acid hybrids
(65–88). Example: synthesis of (R)-(1-(3-(4-fluorobenzylamino)-
3-oxopropyl)-1H-1,2,3-triazol-4-yl)methyl 2-amino-3-
phenylpropanoate (68)
Compound 44 (0.57 mmol, 0.3 g) was dissolved in dichloro-
methane (10 mL). To this solution p-toluene sulphonic acid
(pTSA) (1.71 mmol, 0.32 g) was added. The reaction was stirred
for 3 h at room temperature. After completion of the reaction,
it was neutralized by using sat. sodium bicarbonate solution
and the compound was extracted by ethyl acetate, washed with
water and brine to get final compound (68).
(R)-(1-(3-(Benzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)
methyl 2-amino-3-phenylpropanoate (65). Yellow solid, yield
85%. Rf = 0.69 (10% MeOH in DCM). Mp 165–167 °C.
1H NMR
(400 MHz, DMSO-d6) δ: 7.86 (s, 1H), 7.29–7.15 (m, 10H), 6.68
(brs, 1H), 5.17 (s, 2H), 4.57 (t, J = 6.7 Hz, 2H), 4.49 (s, 2H), 4.25
(d, J = 5.6 Hz, 2H), 3.63–3.60 (m, 1H), 3.17–3.12 (m, 2H), 2.79
(t, J = 7.3 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ: 173.89, 169.13,
162.49, 142.56, 137.85, 133.70, 129.54, 128.68, 127.69, 127.31,
126.85, 123.08, 57.28, 55.91, 46.19, 43.63, 40.65, 36.42. IR
νmax (neat)/cm
−1 3290 (NH2) and 3070 (CH). MS (ESI), m/z:
408.2 [M + H]+.
(R)-(1-(3-(Benzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)
methyl pyrrolidine-2-carboxylate (66). Yellow oil, yield 89%.
Rf = 0.33 (10% MeOH in DCM).
1H NMR (300 MHz, DMSO-d6)
δ: 8.51 (brs, 1H), 7.87 (s, 1H), 7.32–7.15 (m, 5H), 5.14 (brs, 1H),
4.58 (t, J = 6.9 Hz, 2H), 4.50 (s, 2H), 4.26 (d, J = 5.7 Hz, 2H),
3.64–3.59 (m, 1H), 3.23–3.17 (m, 2H), 2.78 (t, J = 6.6 Hz, 2H),
2.01–1.91 (m, 2H), 1.72–1.65 (m, 2H). 13C NMR (75 MHz,
CDCl3) δ: 173.24, 169.35, 148.04, 138.37, 128.39, 127.59,
127.11, 122.66, 60.03, 56.07, 46.12, 43.20, 36.20, 30.78, 29.54,
24.32. IR νmax (neat)/cm
−1 3290 (NH2) and 3070 (CH). MS (ESI),
m/z: 358.6 [M + H]+.
(R)-(1-(3-(Benzylamino)-3-oxopropyl)-1H-1,2,3-triazol-4-yl)
methyl 2-amino-3-(1H-indol-3-yl)propanoate (67). Yellow oil,
yield 88%. Rf = 0.41 (10% MeOH in DCM).
1H NMR (300 MHz,
CDCl3) δ: 8.96 (s, 1H), 7.48 (d, J = 7.5 Hz, 1H), 7.28 (d, J =
7.8 Hz, 1H), 7.19–6.96 (m, 8H), 6.74 (brs, 1H), 6.66 (s, 1H),
5.13–4.97 (m, 2H), 4.59–4.46 (m, 2H), 4.27 (d, J = 5.4 Hz, 2H),
3.75 (t, J = 6.0 Hz, 1H), 3.07–3.04 (m, 1H), 2.78–2.70 (m, 3H).
13C NMR (75 MHz, CDCl3) δ: 174.98, 169.45, 142.46, 137.78,
136.22, 133.67, 128.67, 127.52, 124.81, 123.38, 121.88, 119.35,
118.70, 111.37, 110.13, 57.94, 55.16, 46.14, 43.62, 35.83, 30.41.
IR νmax (neat)/cm
−1 3391 (NH2) and 3068 (CH). MS (ESI), m/z:
445.0 [M − H]−, 447.0 [M + H]+.
(R)-(1-(3-(4-Fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-phenylpropanoate (68). Creamish solid,
yield 85%. Rf = 0.67 (10% MeOH in DCM). Mp 184–186 °C.
1H NMR (300 MHz, CDCl3) δ: 7.51 (s, 1H), 7.21–7.16 (m, 3H),
7.08–7.03 (m, 4H), 6.89 (t, J = 8.7 Hz, 2H), 6.52 (brs, 1H), 5.09
(s, 2H), 4.57 (t, J = 5.6 Hz, 2H), 4.26 (d, J = 5.4 Hz, 2H),
3.66–3.62 (m, 1H), 2.99–2.93 (m, 1H), 2.81–2.72 (m, 3H). 13C
NMR (75 MHz, CDCl3) δ: 174.59, 169.07, 160.52, 142.28,
136.92, 133.70, 129.41, 129.30, 128.54, 126.85, 125.03, 115.65,
57.84, 55.66, 46.19, 42.91, 40.89, 36.16. IR νmax (neat)/cm
−1
3283 (NH2) and 3074 (CH). MS (ESI), m/z: 426.2 [M + H]
+.
(R)-(1-(3-(4-Fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl pyrrolidine-2-carboxylate (69). Light yellow solid,
yield 89%. Rf = 0.33 (10% MeOH in DCM). Mp = 70–76 °C.
1H NMR (400 MHz, CDCl3) δ: 7.60 (s, 1H), 7.16–7.13 (m, 2H),
7.02–6.98 (m, 2H), 5.94 (brs, 1H), 4.75 (s, 2H), 4.70 (t, J = 6.1
Hz, 2H), 4.36 (d, J = 5.8 Hz, 2H), 3.62–3.57 (m, 1H), 3.12–3.03
(m, 2H), 2.86 (t, J = 6.2 Hz, 2H), 2.23–2.07 (m, 2H), 1.86–1.74
(m, 2H). 13C NMR (75 MHz, CDCl3) δ: 173.98, 169.40, 160.25,
148.02, 134.24, 129.31, 127.74, 126.89, 122.70, 115.31, 56.09,
46.12, 42.49, 36.21, 29.53, 24.46. IR νmax (neat)/cm
−1 3290
(NH2) and 3070 (CH). MS (ESI), m/z: 376.0 [M + H]
+.
(R)-(1-(3-(4-Fluorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-(1H-indol-3-yl)propanoate (70). Yellow
oil, yield 90%. Rf = 0.41 (10% MeOH in DCM).
1H NMR
(300 MHz, CDCl3) δ: 8.81 (s, 1H), 7.48 (d, J = 7.8 Hz, 1H), 7.27
(d, J = 8.1 Hz, 1H), 7.11–6.98 (m, 5H), 6.87 (t, J = 8.2 Hz, 2H),
6.64–6.58 (m, 2H), 5.14–4.96 (m, 2H), 4.54–4.42 (m, 2H), 4.22
(d, J = 5.7 Hz, 2H), 3.74 (t, J = 6.0 Hz, 1H), 3.11–3.00 (m, 2H),
2.84–2.77 (m, 2H). 13C NMR (75 MHz, CDCl3) δ: 175.13, 169.42,
142.56, 136.19, 133.53, 129.27, 127.64, 124.88, 123.23, 121.94,
119.41, 118.76, 115.66, 111.32, 110.33, 57.85, 55.23, 46.09,
42.92, 35.73, 30.53. IR νmax (neat)/cm
−1 3272 (NH2) and 3074
(CH). MS (ESI), m/z: 463.0 [M − H]−, 465.2 [M + H]+.
(R)-(1-(3-(4-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-phenylpropanoate (71). Creamish solid,
yield 88%. Rf = 0.43 (10% MeOH in DCM). Mp 120–122 °C.
1H NMR (400 MHz, DMSO-d6) δ: 7.97 (s, 1H), 7.34 (d, J =
8.2 Hz, 2H), 7.28–7.12 (m, 7H), 6.92–6.88 (m, 1H), 5.18–5.10
(m, 2H), 4.61–4.55 (m, 2H), 4.49 (s, 2H), 4.24–4.23 (m, 2H),
3.61–3.58 (m, 1H), 2.88–2.77 (m, 4H). 13C NMR (75 MHz,
CDCl3) δ: 173.66, 169.09, 157.13, 142.17, 136.45, 133.32,
129.31, 128.78, 128.52, 127.01, 125.07, 124.24, 58.20, 54.43,
46.25, 42.93, 40.92, 36.26. IR νmax (neat)/cm
−1 3294 (NH2) and
3070 (CH). MS (ESI), m/z: 442.0 [M + H]+.
(R)-(1-(3-(4-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl pyrrolidine-2-carboxylate (72). Yellow oil, yield
90%. Rf = 0.37 (10% MeOH in DCM).
1H NMR (300 MHz,
CDCl3) δ: 8.55 (s, 1H), 7.86 (s, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.17
(d, J = 8.4 Hz, 2H), 5.16 (brs, 1H), 4.57 (t, J = 6.8 Hz, 2H), 4.49
(s, 2H), 4.24 (d, J = 6.0 Hz, 2H), 3.65–3.60 (m, 2H), 3.04–2.98
(m, 1H), 2.78 (t, J = 6.8 Hz, 2H), 2.01–1.89 (m, 2H), 1.78–1.67
(m, 2H). 13C NMR (75 MHz, CDCl3) δ: 172.24, 169.18, 148.20,
138.78, 128.92, 127.67, 127.42, 122.02, 61.24, 56.29, 46.23,
42.84, 36.28, 31.83, 29.56, 24.56. IR νmax (neat)/cm
−1 3284
(NH2) and 3078 (CH). MS (ESI), m/z: 392.0 [M + H]
+.
(R)-(1-(3-(4-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-(1H-indol-3-yl)propanoate (73). Yellow
oil, yield 87%. Rf = 0.67 (10% MeOH in DCM).
1H NMR
(400 MHz, CDCl3) δ: 8.57 (s, 1H), 7.59 (d, J = 7.3 Hz, 1H), 7.37
(d, J = 7.9 Hz, 1H), 7.28 (brs, 2H), 7.19–7.11 (m, 2H), 7.15–7.07
(m, 3H), 6.68 (s, 1H), 5.95 (brs, 1H), 5.29–5.10 (m, 2H),
Organic & Biomolecular Chemistry Paper
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4.63–4.58 (m, 2H), 4.35–4.34 (m, 2H), 3.87 (t, J = 6.1 Hz, 1H),
3.17–3.15 (m, 2H), 2.95–2.85 (m, 2H). 13C NMR (75 MHz,
CDCl3) δ: 174.39, 169.56, 142.32, 136.78, 133.54, 128.74,
128.51, 127.72, 125.31, 123.24, 121.63, 119.39, 118.43, 111.33,
109.45, 58.01, 54.23, 46.57, 42.81, 35.76, 30.42. IR νmax (neat)/
cm−1 3264 (NH2) and 3063 (CH). MS (ESI), m/z: 479.0 [M −
H]−, 481.2 [M + H]+.
(R)-(1-(3-(2-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-phenylpropanoate (74). Yellow oil, yield
84%. Rf = 0.53 (10% MeOH in DCM).
1H NMR (300 MHz,
CDCl3) δ: 7.49 (s, 1H), 7.24–7.19 (m, 5H), 7.04–6.99 (m, 4H),
6.58 (brs, 1H), 5.20 (s, 2H), 4.58 (t, J = 6.2 Hz, 2H), 4.38 (s, 2H),
4.20–4.16 (m, 2H), 3.72–3.68 (m, 1H), 3.01–2.76 (m, 4H). 13C
NMR (75 MHz, CDCl3) δ: 174.32, 169.40, 161.23, 147.45,
135.18, 133.49, 129.87, 129.52, 128.99, 128.26, 127.06, 125.91,
123.05, 56.09, 54.23, 46.14, 43.24, 41.56, 36.29. IR νmax (neat)/
cm−1 3279 (NH2) and 3067 (CH). MS (ESI), m/z: 442.2 [M + H]
+.
(R)-(1-(3-(2-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl pyrrolidine-2-carboxylate (75). Yellow oil, yield
92%. Rf = 0.35 (10% MeOH in DCM).
1H NMR (300 MHz,
CDCl3) δ: 8.55 (brs, 1H), 7.87 (s, 1H), 7.44–7.41 (m, 1H),
7.31–7.27 (m, 2H), 7.17–7.14 (m, 1H), 5.14 (brs, 1H), 4.58 (t, J =
6.8 Hz, 2H), 4.50 (s, 2H), 4.31 (d, J = 6.6 Hz, 2H), 3.78–3.62 (m,
1H), 3.21–3.14 (m, 2H), 2.83 (t, J = 6.6 Hz, 2H), 2.11–2.02 (m,
1H), 1.95–1.84 (m, 3H). 13C NMR (75 MHz, CDCl3) δ: 173.42,
169.44, 147.49, 135.22, 133.46, 129.81, 129.50, 128.96, 128.43,
127.05, 123.02, 60.23, 56.09, 46.16, 41.53, 36.29, 29.69, 24.56.
IR νmax (neat)/cm
−1 3279 (NH2) and 3074 (CH). MS (ESI), m/z:
392.0 [M + H]+.
(R)-(1-(3-(2-Chlorobenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-(1H-indol-3-yl)propanoate (76). Yellow
oil, yield 82%. Rf = 0.50 (10% MeOH in DCM).
1H NMR
(300 MHz, CDCl3) δ: 8.83 (s, 1H), 7.47 (brs, 1H), 7.29–6.96 (m,
8H), 6.68 (s, 1H), 6.59 (s, 1H), 5.16–4.97 (m, 2H), 4.58 (s, 2H),
4.53 (t, J = 6.3 Hz, 2H), 4.36 (d, J = 5.4 Hz, 2H), 3.08–3.06 (m,
1H), 2.80–2.72 (m, 3H). 13C NMR (75 MHz, CDCl3) δ: 174.65,
169.52, 147.43, 142.39, 135.14, 133.49, 129.89, 129.53, 129.02,
127.06, 124.89, 123.03, 121.95, 119.44, 118.68, 111.36, 109.95,
57.96, 56.04, 46.12, 41.58, 36.25, 29.68. IR νmax (neat)/cm
−1
3260 (NH2) and 3063 (CH). MS (ESI), m/z: 479.0 [M − H]−,
481.2 [M + H]+.
(R)-(1-(3-(4-Methylbenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-phenylpropanoate (77). Light yellow
solid, yield 89%. Rf = 0.50 (10% MeOH in DCM). Mp
168–170 °C. 1H NMR (300 MHz, CDCl3) δ: 7.52 (d, J = 10.8 Hz,
1H), 7.19–6.98 (m, 9H), 6.54–6.36 (m, 1H), 5.09 (s, 2H),
4.58–4.54 (m, 2H), 4.24 (s, 2H), 3.66 (brs, 1H), 2.81–2.74 (m,
2H), 2.47 (brs, 2H), 2.23 (s, 3H). 13C NMR (75 MHz, CDCl3)
δ: 174.38, 169.17, 147.49, 142.19, 137.28, 134.79, 129.33,
128.56, 127.70, 126.88, 125.06, 123.03, 57.94, 55.59, 46.21,
43.43, 40.66, 36.43, 21.07. IR νmax (neat)/cm
−1 3298 (NH2) and
3067 (CH). MS (ESI), m/z: 422.2 [M + H]+.
(R)-(1-(3-(4-Methylbenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl pyrrolidine-2-carboxylate (78). Light yellow solid,
yield 83%. Rf = 0.26 (10% MeOH in DCM). Mp 109–111 °C.
1H NMR (300 MHz, CDCl3) δ: 8.43 (brs, 1H), 7.85 (s, 1H),
7.11–7.04 (m, 4H), 4.57 (t, J = 6.8 Hz, 2H), 4.50 (s, 2H), 4.21 (d,
J = 5.7 Hz, 2H), 3.68–3.63 (m, 1H), 3.19–2.94 (m, 2H), 2.77 (t,
J = 5.7 Hz, 2H), 2.29 (s, 3H), 1.99–1.90 (m, 2H), 1.71–1.64 (m,
2H). 13C NMR (75 MHz, CDCl3) δ: 172.10, 169.42, 148.27,
136.58, 136.26, 129.25, 128.56, 127.63, 123.25, 59.61, 55.51,
46.14, 42.92, 35.99, 30.65, 29.38, 21.11. IR νmax (neat)/cm
−1
3294 (NH2) and 3074 (CH). MS (ESI), m/z: 372.2 [M + H]
+.
(R)-(1-(3-(4-Methylbenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-(1H-indol-3-yl)propanoate (79). Yellow
oil, yield 85%. Rf = 0.50 (10% MeOH in DCM).
1H NMR
(300 MHz, CDCl3) δ: 8.63 (s, 1H), 7.52 (brs, 1H), 7.32–6.97 (m,
8H), 6.64 (s, 1H), 5.99–5.91 (m, 1H), 5.19–5.00 (m, 2H),
4.65–4.51 (m, 2H), 4.27–4.25 (m, 2H), 3.79 (brs, 1H), 3.09–3.08
(m, 1H), 2.79–2.74 (m, 3H), 2.25 (s, 3H). 13C NMR (75 MHz,
CDCl3) δ: 174.89, 169.76, 142.41, 137.54, 136.38, 133.45,
129.54, 128.32, 127.43, 125.21, 123.67, 121.83, 119.75, 118.32,
111.63, 109.23, 58.42, 54.61, 46.21, 43.68, 35.42, 28.35, 21.07.
IR νmax (neat)/cm
−1 3279 (NH2) and 3059 (CH). MS (ESI), m/z:
459.2 [M − H]−, 461.2 [M + H]+, 483.2 [M + Na]+.
(R)-(1-(3-(4-Methoxybenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-phenylpropanoate (80). Light yellow solid,
yield 87%. Rf = 0.57 (10% MeOH in DCM). Mp 168–170 °C.
1H NMR (400 MHz, DMSO-d6) δ: 7.85 (s, 1H), 7.30–7.18 (m,
4H), 7.14–7.08 (m, 3H), 6.86–6.83 (m, 2H), 6.68–6.65 (m, 1H),
5.09 (s, 2H), 4.60–4.54 (m, 2H), 4.49 (s, 2H), 4.18 (d, J = 5.6 Hz,
2H), 3.72 (s, 3H), 3.58–3.56 (m, 1H), 2.85–2.73 (m, 4H).
13C NMR (75 MHz, CDCl3) δ: 173.65, 168.78, 158.43, 142.38,
137.61, 133.83, 129.11, 128.64, 126.90, 125.11, 122.93, 56.35,
55.30, 52.39, 46.22, 43.24, 40.43, 36.36. IR νmax (neat)/cm
−1
3286 (NH2) and 3070 (CH). MS (ESI), m/z: 436.5 [M − H]−,
438.1 [M + H]+.
(R)-(1-(3-(4-Methoxybenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methylpyrrolidine-2-carboxylate (81). Yellow solid, yield
90%. Rf = 0.14 (10% MeOH in DCM).
1H NMR (300 MHz,
CDCl3) δ: 8.46 (brs, 1H), 7.86 (s, 1H), 7.09 (d, J = 8.4 Hz, 2H),
6.85 (d, J = 8.4 Hz, 2H), 4.57 (t, J = 6.8 Hz, 2H), 4.50 (s, 2H),
4.18 (d, J = 5.7 Hz, 2H), 3.72 (s, 3H), 3.69–3.64 (m, 1H),
3.42–3.37 (m, 2H), 2.76 (t, J = 7.0 Hz, 2H), 1.96–1.91 (m, 2H),
1.78–1.65 (m, 2H). 13C NMR (75 MHz, CDCl3) δ: 173.65,
169.36, 148.26, 138.37, 131.56, 128.98, 123.26, 114.21,
61.19, 57.23, 55.51, 46.15, 42.00, 36.01, 30.63, 29.37, 24.31.
IR νmax (neat)/cm
−1 3290 (NH2) and 3074 (CH). MS (ESI), m/z:
388.2 [M + H]+.
(R)-(1-(3-(4-Methoxybenzylamino)-3-oxopropyl)-1H-1,2,3-triazol-
4-yl)methyl 2-amino-3-(1H-indol-3-yl)propanoate (82). Yellow
solid, yield 89%. Rf = 0.53 (10% MeOH in DCM). Mp
150–154 °C. 1H NMR (400 MHz, CDCl3) δ: 8.41 (s, 1H), 7.91 (s,
1H), 7.48 (d, J = 7.8 Hz, 1H), 7.32 (d, J = 7.9 Hz, 1H), 7.09–7.06
(m, 5H), 6.96 (t, J = 7.4 Hz, 1H), 6.89 (m, 2H), 5.06 (s, 2H), 4.57
(t, J = 6.4 Hz, 2H), 4.17 (d, J = 5.6 Hz, 2H), 3.71 (s, 3H),
3.66–3.63 (m, 1H), 3.03–2.89 (m, 2H), 2.76 (t, J = 6.5 Hz, 2H).
13C NMR (75 MHz, CDCl3) δ: 173.12, 169.45, 142.79, 136.32,
133.59, 129.54, 128.43, 127.61, 125.51, 123.21, 121.87, 119.37,
118.63, 114.21, 111.53, 109.25, 58.53, 55.21, 54.76, 46.62,
43.38, 35.54, 30.56. IR νmax (neat)/cm
−1 3279 (NH2) and 3082
(CH). MS (ESI), m/z: 475.2 [M − H]−, 477.2 [M + H]+.
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(R)-(1-(3-(4-(Trifluoromethyl)benzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-amino-3-phenylpropanoate (83).
Light yellow solid, yield 88%. Rf = 0.57 (10% MeOH in DCM).
Mp 158–160 °C. 1H NMR (400 MHz, DMSO-d6) δ: 7.87
(s, 1H), 7.65 (d, J = 8.0 Hz, 2H), 7.36 (t, J = 8.4 Hz, 2H),
7.30–7.18 (m, 4H), 7.12 (d, J = 6.5 Hz, 1H), 6.68–6.66 (m, 1H),
5.09 (m, 2H), 4.58 (t, J = 7.7 Hz, 2H), 4.49 (s, 2H), 4.34 (d, J =
5.6 Hz, 2H), 3.60–3.57 (m, 1H), 2.84–2.76 (m, 4H). 13C NMR
(75 MHz, CDCl3) δ: 174.15, 169.49, 146.34, 142.24, 141.93,
129.30, 128.89, 128.53, 127.76, 127.03, 125.61, 125.09, 123.15,
56.06, 52.65, 46.18, 43.10, 36.28. IR νmax (neat)/cm
−1 3298
(NH2) and 3070 (CH). MS (ESI), m/z: 474.8 [M − H]−, 476.3
[M + H]+.
(R)-(1-(3-(4-Trifluoromethylbenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl pyrrolidine-2-carboxylate (84). Yellow
oil, yield 89%. Rf = 0.35 (10% MeOH in DCM).
1H NMR
(300 MHz, CDCl3) δ: 8.43 (brs, 1H), 7.56 (s, 1H), 7.40–7.21 (m,
4H), 5.23 (brs, 1H), 4.64 (m, 2H), 4.47 (s, 2H), 4.34 (d, J =
6.5 Hz, 2H), 3.78–3.64 (m, 1H), 3.32–3.21 (m, 2H), 2.87 (t, J =
8.8 Hz, 2H), 2.31–2.21 (m, 1H), 2.08–1.77 (m, 3H). 13C NMR
(75 MHz, CDCl3) δ: 174.12, 169.72, 149.58, 137.26, 129.65,
127.78, 126.92, 125.61, 123.18, 58.16, 54.48, 46.09, 43.14,
35.51, 31.03, 29.70, 24.32. IR νmax (neat)/cm
−1 3298 (NH2) and
3095 (CH). MS (ESI), m/z: 426.05 [M + H]+.
(R)-(1-(3-(4-(Trifluoromethyl)benzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-amino-3-(1H-indol-3-yl)propanoate
(85). Yellow oil, yield 85%. Rf = 0.64 (10% MeOH in DCM).
1H NMR (400 MHz, CDCl3) δ: 8.96–8.94 (m, 1H), 8.15 (d, J =
8.0 Hz, 1H), 8.06–8.00 (m, 3H), 7.64 (t, J = 7.2 Hz, 1H),
7.57–7.51 (m, 4H), 7.15 (t, J = 7.1 Hz, 1H), 6.99 (s, 1H), 4.97 (s,
2H), 4.65–4.59 (m, 2H), 4.43–4.38 (m, 2H), 3.51–3.48 (m, 1H),
2.96 (brs, 2H), 2.88 (brs, 2H). 13C NMR (75 MHz, CDCl3)
δ: 175.40, 169.53, 147.34, 141.88, 136.45, 133.46, 129.99,
128.87, 127.76, 125.61, 124.54, 123.16, 121.78, 119.64, 118.74,
110.98, 109.12, 58.67, 55.89, 46.20, 43.12, 36.23, 29.68. IR νmax
(neat)/cm−1 3284 (NH2) and 3063 (CH). MS (ESI), m/z: 515.3
[M + H]+.
(R)-(1-(3-(4-Trifluoromethoxybenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-amino-3-phenylpropanoate (86).
Yellow oil, yield 89%. Rf = 0.57 (10% MeOH in DCM).
1H NMR
(300 MHz, CDCl3) δ: 7.57 (s, 1H), 7.32–7.11 (m, 9H), 6.54 (brs,
1H), 5.14 (s, 2H), 4.61 (t, J = 5.8 Hz, 2H), 4.51 (s, 2H), 4.33–4.25
(m, 2H), 3.65–3.52 (m, 1H), 3.12–3.01 (m, 2H), 2.82 (t, J =
6.8 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ: 172.87, 168.71,
157.26, 142.77, 137.56, 134.09, 130.45, 128.92, 127.87, 127.45,
126.09, 123.29, 121.56, 58.51, 54.71, 46.31, 43.71, 40.83, 35.55.
IR νmax (neat)/cm
−1 3287 (NH2) and 3056 (CH). MS (ESI), m/z:
492.3 [M + H]+.
(R)-(1-(3-(4-Trifluoromethoxybenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl pyrrolidine-2-carboxylate (87). Light
yellow oil, yield 89%. Rf = 0.38 (10% MeOH in DCM).
1H NMR
(300 MHz, CDCl3) δ: 8.54 (brs, 1H), 7.89 (s, 1H), 7.67–7.43
(m, 2H), 7.31–7.23 (m, 2H), 5.20 (brs, 1H), 4.64 (t, J = 7.2 Hz,
2H), 4.54 (s, 2H), 4.29 (d, J = 6.7 Hz, 2H), 3.78–3.62
(m, 1H), 3.28–3.21 (m, 2H), 2.89 (t, J = 7.6 Hz, 2H), 2.22–2.04
(m, 2H), 1.89–1.72 (m, 2H). 13C NMR (75 MHz, CDCl3)
δ: 173.45, 169.52, 149.23, 138.45, 129.34, 128.43, 127.89,
127.34, 122.89, 60.56, 56.45, 46.58, 43.76, 36.52, 30.93, 29.81,
24.56. IR νmax (neat)/cm
−1 3290 (NH2) and 3065 (CH). MS (ESI),
m/z: 442.3 [M + H]+.
(R)-(1-(3-(4-Trifluoromethoxybenzylamino)-3-oxopropyl)-1H-
1,2,3-triazol-4-yl)methyl 2-amino-3-(1H-indol-3-yl)propanoate
(88). Yellow oil, yield 89%. Rf = 0.62 (10% MeOH in DCM).
1H NMR (300 MHz, CDCl3) δ: 8.73 (s, 1H), 7.65 (d, J = 7.8 Hz,
1H), 7.47 (d, J = 7.8 Hz, 1H), 7.36–7.25 (m, 5H), 7.12–6.99 (m,
3H), 6.46 (s, 1H), 5.23–5.14 (m, 2H), 4.60–4.53 (m, 2H), 4.32 (d,
J = 6.0 Hz, 2H), 3.87–3.76 (m, 1H), 3.25–3.11 (m, 2H), 2.90–2.77
(m, 2H). 13C NMR (75 MHz, CDCl3) δ: 174.24, 169.48, 156.24,
143.43, 137.89, 135.23, 128.56, 127.51, 127.32, 124.43, 123.29,
122.56, 121.76, 119.32, 118.67, 111.48, 109.62, 58.45, 54.76,
46.23, 43.54, 35.72, 30.35. IR νmax (neat)/cm
−1 3294 (NH2) and
3066 (CH). MS (ESI), m/z: 531.3 [M + H]+.
Biology
In vitro anti-Candida activity. The anticandidal assessment
of title compounds (65–88) was performed by the broth
dilution technique according to the standard protocol of
NCCLS, 2012.30 In this study, C. albicans ATCC 90028,
C. albicans 10261, C. glabrata ATCC 90030, C. tropicalis ATCC
750 and FLC-sensitive/resistant clinical isolates of C. albicans
were used for anticandidal activity assessment. Fluconazole
was used as a positive control. Varying concentrations (1000 to
7.8 µg mL−1) of test compounds were dispensed into a 96-well
plate in Sabouraud dextrose broth medium in a final volume
of 100 µL. Candida cells were harvested and their turbidity was
assessed according to the McFarland standards. Then, 100 µL
of cells (approximately 2.5 × 103 cells per mL) were dispensed
into the 96 wells and incubated at 37 °C for 24 h. After incu-
bation, the growth was measured turbidometrically at 600 nm
using a Thermo Multiskan spectrophotometer. IC50 was deter-
mined as 50% inhibition of Candida growth and calculated by
plotting a graph between the concentration (log10) and %
inhibition.
Time kill curve study. The fungicidal or fungistatic effect of
lead inhibitors 68 and 70 was determined by the time–kill
curve assay according to the method reported by Jiang et al.31
For standard as well as resistant strains of C. albicans, the cells
were exposed to 60 and 120 µg mL−1 concentrations of 68 and
70. Fluconazole (125 and 1000 µg mL−1) was used as a positive
control against standard and FLC-resistant C. albicans, respect-
ively. The untreated cells were used as a negative control. All
time–kill curve experiments were conducted in triplicate and
the mean colony count data (log10 CFU mL
−1) were plotted as
a function of time for each strain.
Proteinase and phospholipase assay. Previously identified
proteinase positive standard C. albicans ATCC 90028 along
with FLC-sensitive and resistant clinical isolates of C. albicans
were used for this study. 1.5 mL of the 24 h old Candida cells
were transferred into micro-centrifuge tubes and centrifuged
at 3000 rpm for 5 min. The pellets obtained were washed in
phosphate buffer saline (PBS) twice and centrifuged to remove
the residual medium. After standardizing the suspensions
Organic & Biomolecular Chemistry Paper
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(MacFarland standard), the cells were exposed to 60 and
120 µg mL−1 of lead inhibitors (68 and 70) for 1 h. Then, 1 µL
from each cell suspension treated with the test compound was
plated at equidistant points on proteinase and phospholipase
agar media and incubated at 37 °C for 3–4 days.32 The for-
mation of a transparent halo around the Candida colonies
indicated the effect of the test compounds on extracellular
enzyme secretion. Enzyme activity was measured by dividing
the diameter of the colony by the diameter of the colony plus
zone of clearance.33 The experiment was performed in
triplicate.
Transmission electron microscopy (TEM) analysis. The mor-
phology of Candida cells was analyzed using TEM following
the standard protocol.34 Mid-log phase cells were harvested,
standardized (A600 ≈ 0.1) and exposed to a 120 µg mL−1 con-
centration of test inhibitors 68 and 70 for 1 h. Then, the cells
were washed thrice with PBS to remove the residual medium
and fixed overnight in 2.5% glutaraldehyde in phosphate/
magnesium buffer (40 mM K2HPO4/KH2PO4, pH 6.5, 0.5 mM
MgCl2). The cells were washed twice for 15 min in 0.1 M
sodium phosphate buffer (pH 6.0) and post-fixed for 2 h in
2% osmium tetroxide. Again, the cells were washed twice for
15 min in distilled water and then en bloc stained with 1%
uranyl acetate (aqueous) for 30 min. After two further
washes, the cells were dehydrated in 95% and 100% ethanol.
The cells were exposed to propylene oxide for 2 × 10 min and
infiltrated for 1 h in a 1 : 1 propylene/epoxy embedding
material (Epon) mixture and then overnight in fresh Epon.
After polymerization for 48 h at 60 °C, ultrathin sections
were cut using a microtome (LeicaEM UC6) and transferred
onto a copper grid. The samples were stained with uranyl
acetate (saturated solution of uranyl acetate in 50% alcohol)
followed by lead citrate. The samples were washed three
times in Milli-Q (MQ) water and dried by touching with
Whatman filter paper. The sections were examined with a
Jeol (Japan) JEM-2100F transmission electron microscope at
120 kV.
Ergosterol estimation assay. The total intracellular sterols
were extracted as reported earlier with slight modifications.22
Three separate conical flasks containing 30, 60 and 120 µg
mL−1 of compounds 68 and 70 in Sabouraud dextrose broth
were inoculated with fresh cells of C. albicans ATCC 90028
(standard) and FLC-resistant C. albicans. Fluconazole (40 µg
mL−1) was used as a positive control while the untreated cells
as a negative control for comparison. All the conical flasks
were incubated at 35 °C for 16 h. After incubation, the cells
were harvested at their stationary phase and the weight of the
pellet was determined. The pellet was treated with 25% alco-
holic potassium hydroxide (KOH) solution followed by incu-
bation at 85 °C for 1 h. After incubation, sterol was extracted
by the addition of the n-heptane : distilled water (1 : 3)
mixture. The heptane layers were transferred into a fresh test
tube, diluted five-fold in 100% ethanol and scanned spectro-
photometrically between 240 and 300 nm. The presence of
ergosterol and the late sterol intermediate 24(28)DHE in the
extracted sample resulted in a characteristic four peak curve.
The absence of detectable ergosterol in the extract was indi-
cated as a flat line. The ergosterol content was calculated as a
percentage wet weight of the cell by using the following the
equation:
%Ergosterolþ%24ð28ÞDHE ¼ ½ðA281:5=290Þ  F=pellet weight
where, %24(28)DHE = [(A230/518) × F]/pellet weight, A281.5 and
A230 are absorbances at 281.5 nm and 230 nm, respectively,
and F is the factor for dilution in ethanol.
Cell proliferation assay. MTT (3-(4,5-dimethyl-2-yl)-2,5-
diphenyl tetrazolium bromide), Dulbecco’s modified Eagle’s
medium (DMEM), 0.25% trypsin, and a 0.02% EDTA mixture
were purchased from Hi Media (Mumbai, India). Fetal bovine
serum (FBS) was obtained from Gibco (Grand Island, NY).
The human embryonic kidney (HEK293) cell line was pro-
cured from the National Centre for Cell Sciences (NCCS),
Pune, India. The cells were cultured and maintained as a
monolayer in DMEM supplemented with 10% FBS and anti-
biotics (100 units per mL penicillin and 100 µg mL−1 strepto-
mycin) at 37 °C under a humidified atmosphere of 5% CO2
in T-25 flasks. The cells were sub-cultured twice in a week.
A cell count of approximately 2 × 104 cells per well were
seeded in a 96-well plate (150 µL per well) and incubated for
24 h before treatment. The cells were then treated with
varying concentrations (10–600 µg mL−1) of the test com-
pounds. After 48 h of incubation at 37 °C, the exhausted
serum supplemented medium was removed and serum free
media (50 µL) was added into each well. After that, 20 µL per
well of MTT at a concentration of 5 mg mL−1 in PBS was
added to each well and the plates were incubated for 4 h at
37 °C. Formazan crystals, the metabolized MTT product,
were solubilized in DMSO (150 µL per well) and were quanti-
fied by reading the absorbance at 570 nm after incubation of
10 min on an iMark Microplate Reader (Bio-Rad, Hercules,
CA). All assays were performed in triplicate. Percent viability
was taken as the relative absorbance of treated versus
untreated control cells.35
Hemolytic assay. The hemolytic activities of the test inhibi-
tors 68 and 70 and the conventional antifungal drug FLC
were determined on human red blood cells (hRBCs).36
Human erythrocytes from healthy individuals were collected
in tubes containing EDTA as an anti-coagulant. The erythro-
cytes were harvested by centrifugation for 10 min at 2000 rpm
and 20 °C, and washed three times in PBS. To the pellet, PBS
was added to yield a 10% (v/v) erythrocytes/PBS suspension.
The 10% suspension of erythrocytes was then further diluted
with PBS at a 1 : 10 ratio. 100 µL of the final diluted erythro-
cytes was added to 100 µL of PBS having a previously deter-
mined concentration gradient (1000 to 7.8 µg mL−1) of test
compounds in micro-centrifuge tubes. Total hemolysis was
achieved with 1% Triton X-100. The tubes were incubated for
1 h at 37 °C and then centrifuged for 10 min at 2000 rpm and
at room temperature. From the supernatant fluid, 150 µL was
transferred to a flat-bottomed microtiter plate (Tarson), and
the absorbance was measured spectrophotometrically at
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450 nm by using a Thermo Multiskan spectrophotometer.
The hemolysis percentage was calculated by following the
equation:
Where A450 is the absorbance at 450 nm.
Modeling the CYP51 like protein structure. The primary
protein sequence of CYP51 was extracted from a protein data-
base at NCBI37 and its homologous sequence from the PDB
with PDB ID-4LXJ.38 Modeller 9.1539 was used to generate
5 models of the Candida CYP51 protein using the S. cervisiae
CYP51 protein (PDB ID-4LXJ) as a template. Structure vali-
dation of these models was performed using Procheck,40 veri-
fied in 3D41 and superimposed using Chimera42 for structure
comparison.
In silico docking. The 3D structures of the two shortlisted
compounds, 68 and 70 were drawn using Chem Draw.43 We
used model 3 for further in silico analysis. The computational
docking method predicts the ligand–macromolecule bound
states with their binding affinities using a scoring function.
We have used AUTODOCK VINA 1.1.244 in the present study
that uses Iterated Local Search Global Optimization algorithm
for local minima search.45,46 We performed in silico blind
docking of the complete protein molecule of model 3 against
the two shortlisted compounds 68 and 70. We used ADT tools
to process the protein and ligand PDBs into ADT desired
format (PDBQT). Protein processing includes removal of water
molecules, addition of hydrogen and charges to the protein
and likewise the ligand was processed (68 and 70) for ADT
format. The grid dimensions of X, Y and Z covering the com-
plete model 3 of the CYP51 protein molecule was 64, 60 and
52 with 1 Å spacing. The dimensions of the centre grid box
were 23.27, 15.94 and 19.74 in the case of whole
CYP51 molecule blind docking. The complex with the
minimum binding energy and involving more number of inter-
actions were chosen as the basis for further interface analysis.
We mapped and visualized these interacting partners in
PyMol.47 Binding affinities of both lead compounds (68 and
70) with the modeled CYP51 were quantitated and are rep-
resented as kcal mol−1. The images were prepared using the
LIGPLOT visualizing program48 and the polar and hydrophobic
contacts between them were noted down.
In vivo assessment of the efficacy of lead inhibitors (68 and
70) against Galleria mellonella larvae. The larvae of the sixth
developmental stage of G. mellonella were obtained from the
Meal Worm Company (Sheffield, England). The larvae of
G. mellonella were stored in wood shavings in the dark at 15 °C
prior to use. The larvae that were chosen for experiments
weighed 0.21 g and were used within 3–4 weeks of receipt. Ten
healthy larvae were placed in sterile 9 cm Petri dishes with
Whatman filter paper inserted inside. A culture of C. albicans
was grown to the stationary phase (1–2 × 108 mL−1) in YEPD
broth at 30 °C and 200 rpm. The cells were harvested by cen-
trifugation (2056g for 5 minutes on a Beckmann GS-6 bench
centrifuge) washed in PBS and re-suspended in PBS at a cell
density of 5 × 105 per 20 µL. The larvae were inoculated by
injecting 20 µL through the last left pro-leg into the haemocoel
using a Myjector syringe (Terumo Europe) and placed at 30 °C
in the dark. One h post inoculation, the larvae were inoculated
with compounds 68 and 70, both at a concentration of 2.5 mg
suspended in PBS, supplemented with 12.5% DMSO (v/v),
through the last right pro-leg. The larvae injected with 20 µL of
PBS supplemented with 12.5% DMSO (v/v) were used as con-
trols. For assessment of larval viability, the larvae were gently
probed with a needle and if no response was observed, the
larvae were considered to be dead.
Three larvae were inoculated with 20 μL of compounds 68
and 70 solutions at concentrations of 1.25 or 2.5 mg mL−1.
The larvae were then incubated at 30 °C, in the dark, for 24 h.
The haemocyte density in the larvae was ascertained by pier-
cing the backs of the anterior end (‘head’) of the three larvae
with a sterile needle and collecting the yellow haemolymph
(‘blood’), ensuring no white flocular material was removed –
this is the fat body and will impede counting. Haemolymph
was diluted to 1 in 10 in cold PBS containing 0.37% (v/v)
2-mercaptoethanol to reduce clotting and melanisation. The
solution was mixed gently by pipetting. Haemocytes were
counted on a haemocytometer (0.0025 mm2, BlauBrand,
Germany) and the density in the original larvae was calculated.
Five larvae of G. mellonella were inoculated with C. albicans
at a density of 5 × 105 per 20 µl and incubated at 30 °C in the
dark. 1 h post inoculation, larvae were inoculated with com-
pounds 68 and 70 both at a concentration of 2.5 mg sus-
pended in PBS supplemented with 12.5% DMSO (v/v). Three
larvae were selected and placed in a sterile pestle with 3 mL of
PBS and ground to a pulp with a mortar. The resulting hom-
ogenate was diluted with PBS and 100 μL of the sample was
plated onto three YEPD-erythromycin plates (to prevent bac-
terial growth). The homogenate was diluted to 1/10 in PBS
prior to plating. The plates were incubated at 30 °C for 24 h
and the colony forming units were enumerated. The fungal
load in the larvae was calculated by multiplying this figure by
the relevant dilution factors.
Conclusions
In summary a novel series of 1,2,3-triazole–amino acid hybrids
was prepared in an attempt to search for potent antifungal
agents that can be effective against the FLC-sensitive and
resistant strains of Candida species. Out of 24, twelve com-
pounds (65, 67–71, 73–74, 79, 82–83, 85) showed comparatively
lower IC50 values against various standard Candida strains and
were found to be non-cytotoxic on the HEK293 cell line up to a
concentration of 200 µg mL−1. Seven compounds (67–68,
70–71, 73, 79, 82) were selected for their inhibitory potential
%Hemolysis ¼ ðA450 of test compound treated sample A450 of buffer treated sampleÞ=
ðA450 of 1% Triton X‐100 treated sample A450 of buffer treated sampleÞ
 100%:
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against FLC sensitive and resistant clinical C. albicans isolates
and identified two lead compounds 68 and 70 with the most
potent antifungal activity against all the strains used. Time kill
testing assay confirmed the fungistatic nature of the lead com-
pounds (68 and 70). They also effectively inhibited the extra-
cellular secretion of the enzymes in proteinase and phopholi-
pase assays against FLC sensitive and resistant clinical
C. albicans isolates. These enzymes are responsible for the
fungal invasion of host tissues and immune suppression. TEM
analysis showed that compounds 68 and 70 caused significant
damage to C. albicans cells. Alterations in the cell wall struc-
ture suggests that these antifungal compounds may cause cell
death resulting from inhibiting the synthetic route of fungal
cell wall formation. The effect of 68 and 70 on the intracellular
ergosterol content in FLC-sensitive and resistant C. albicans
clinical strains were also examined which revealed the inhi-
bition of ergosterol biosynthesis thereby producing an anti-
Candida effect. An overall understanding of the interaction of
the lead inhibitors 68 and 70 with the modeled Candida like
CYP51 protein will help in knowledge based design of better
leads with more potent antifungal activity. Compounds 68 and
70 not only proved to be the most potent anti-Candida agents
in in vitro assays but also displayed promising in vivo efficacy
in the G. mellonella larvae model. The administration of a dose
of 2.5 mg mL−1 of 68 and 70 to the larvae did not affect the via-
bility confirming their non-toxic behaviour. Also, no signifi-
cant alteration in the haemocyte density was observed which
indicated the lack of an immune response. Compound 68
caused about 50% inhibition to the larvae infected with
C. albicans while 70 reduced 70% yeast replication in vivo as
measured at 24 h. Our results strongly support that the lead
inhibitors (68 and 70) provide a good starting point for lead
optimization and efficacy for clinical studies.
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